US20100222631A1 - Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules - Google Patents
Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules Download PDFInfo
- Publication number
- US20100222631A1 US20100222631A1 US12/772,002 US77200210A US2010222631A1 US 20100222631 A1 US20100222631 A1 US 20100222631A1 US 77200210 A US77200210 A US 77200210A US 2010222631 A1 US2010222631 A1 US 2010222631A1
- Authority
- US
- United States
- Prior art keywords
- burst
- target tissue
- electric field
- waveforms
- amplitude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Definitions
- This invention pertains generally to an apparatus and a method for in vitro and in vivo therapeutic and prophylactic treatment of plant, animal, and human tissue, organs, cells and molecules.
- an embodiment according to the present invention pertains to use of non-thermal time-varying magnetic fields configured for optimal coupling to target pathway structures such as molecules, cells, tissue, and organs, using power and amplitude comparison analysis to evaluate a signal to thermal noise ratio (“SNR”) in the target pathway structure.
- SNR signal to thermal noise ratio
- Another embodiment according to the present invention pertains to application of bursts of arbitrary waveform electromagnetic signals to target pathway structures such as molecules, cells, tissues, and organs using ultra lightweight portable coupling devices such as inductors and electrodes, and driver circuitry that can be incorporated into a positioning device such as knee, elbow, lower back, shoulder, foot, and other anatomical wraps, as well as apparel such as garments, footwear, and fashion accessories.
- ultra lightweight portable coupling devices such as inductors and electrodes, and driver circuitry that can be incorporated into a positioning device such as knee, elbow, lower back, shoulder, foot, and other anatomical wraps, as well as apparel such as garments, footwear, and fashion accessories.
- Yet another embodiment according to the present invention pertains to application of steady state periodic signals of arbitrary waveform electromagnetic signals to target pathway structures such as molecules, cells, tissues, and organs.
- therapeutic and prophylactic applications of the present invention are musculoskeletal pain relief, edema reduction, increased local blood flow, microvascular blood perfusion, wound repair, bone repair, osteoporosis treatment and prevention, angiogenesis, neovascularization, enhanced immune response, tissue repair, enhanced transudation, and enhanced effectiveness of pharmacological agents.
- An embodiment according to the present invention can also be used in conjunction with other therapeutic and prophylactic procedures and modalities such as heat, cold, ultrasound, vacuum assisted wound closure, wound dressing, orthopedic fixation devices, and surgical interventions.
- Time-varying electromagnetic fields comprising rectangular waveforms such as pulsing electromagnetic fields (“PEMF”), and sinusoidal waveforms such as pulsed radio frequency fields (“PRF”) ranging from several Hertz to an about 15 to an about 40 MHz range, are clinically beneficial when used as an adjunctive therapy for a variety of musculoskeletal injuries and conditions.
- PEMF pulsing electromagnetic fields
- PRF pulsed radio frequency fields
- EMF devices constitute the standard armamentarium of orthopaedic clinical practice for treatment of difficult to heal fractures.
- the success rate for these devices has been very high.
- the database for this indication is large enough to enable its recommended use as a safe, non-surgical, non-invasive alternative to a first bone graft. Additional clinical indications for these technologies have been reported in double blind studies for treatment of avascular necrosis, tendinitis, osteoarthritis, wound repair, blood circulation and pain from arthritis as well as other musculoskeletal injuries.
- EMF EMF stimulates secretion of growth factors after a short, trigger-like duration.
- Ion/ligand binding processes at a cell membrane are generally considered an initial EMF target pathway structure.
- upregulation such as modulation, of growth factor production as part of normal molecular regulation of bone repair.
- Cellular level studies have shown effects on calcium ion transport, cell proliferation, Insulin Growth Factor (“IGF-II”) release, and IGF-II receptor expression in osteoblasts. Effects on Insulin Growth Factor-I (“IGF-I”) and IGF-II have also been demonstrated in rat fracture callus.
- TGF- ⁇ transforming growth factor beta
- mRNA messenger RNA
- MG-63 human osteoblast-like cell line designated MG-63, wherein there were increases in TGF- ⁇ 1, collagen, and osteocalcin synthesis.
- PEMF stimulated an increase in TGF- ⁇ 1 in both hypertrophic and atrophic cells from human non-union tissue.
- Further studies demonstrated an increase in both TGF- ⁇ 1 mRNA and protein in osteoblast cultures resulting from a direct effect of EMF on a calcium/calmodulin-dependent pathway.
- a preferred embodiment according to the present invention utilizes a Power Signal to Noise Ratio (“Power SNR”) approach to configure bioeffective waveforms and incorporates miniaturized circuitry and lightweight flexible coils.
- Power SNR Power Signal to Noise Ratio
- broad spectral density bursts of electromagnetic waveforms configured to achieve maximum signal power within a bandpass of a biological target, are selectively applied to target pathway structures such as living organs, tissues, cells and molecules.
- Waveforms are selected using a unique amplitude/power comparison with that of thermal noise in a target pathway structure.
- Signals comprise bursts of at least one of sinusoidal, rectangular, chaotic and random wave shapes, have frequency content in a range of about 0.01 Hz to about 100 MHz at about 1 to about 100,000 bursts per second, and have a burst repetition rate from about 0.01 to about 1000 bursts/second.
- Peak signal amplitude at a target pathway structure such as tissue lies in a range of about 1 ⁇ V/cm to about 100 mV/cm.
- Each signal burst envelope may be a random function providing a means to accommodate different electromagnetic characteristics of healing tissue.
- a preferred embodiment according to the present comprises a 20 millisecond pulse burst comprising about 5 to about 20 microsecond symmetrical or asymmetrical pulses repeating at about 1 to about 100 kilohertz within the burst.
- the burst envelope is a modified 1/f function and is applied at random repetition rates.
- a resulting waveform can be delivered via inductive or capacitive coupling.
- SNR signal to noise ratio
- FIG. 1 is a flow diagram of a method for electromagnetic treatment of plant, animal, and human target pathway structures such as tissue, organs, cells, and molecules according to an embodiment of the present invention
- FIG. 2 is a view of control circuitry and electrical coils applied to a knee joint according to a preferred embodiment of the present invention
- FIG. 3 is a block diagram of miniaturized circuitry according to a preferred embodiment of the present invention.
- FIG. 4A is a line drawing of a wire coil such as an inductor according to a preferred embodiment of the present invention.
- FIG. 4B is a line drawing of a flexible magnetic wire according to a preferred embodiment of the present invention.
- FIG. 5 depicts a waveform delivered to a target pathway structure such as a molecule, cell, tissue or organ according to a preferred embodiment of the present invention
- FIG. 6 is a view of a positioning device such as a wrist support according to a preferred embodiment of the present invention.
- FIG. 7 is a graph illustrating maximally increased myosin phosphorylation for a PMRF signal configured according to an embodiment of the present invention.
- FIG. 8 is a graph illustrating a power consumption comparison between a 60 Hz signal and a PEMF signal configured according to an embodiment of the present invention.
- Induced time-varying currents from PEMF or PRF devices flow in a target pathway structure such as a molecule, cell, tissue, and organ, and it is these currents that are a stimulus to which cells and tissues can react in a physiologically meaningful manner.
- the electrical properties of a target pathway structure affect levels and distributions of induced current. Molecules, cells, tissue, and organs are all in an induced current pathway such as cells in a gap junction contact. Ion or ligand interactions at binding sites on macromolecules that may reside on a membrane surface are voltage dependent processes, that is electrochemical, that can respond to an induced electromagnetic field (“E”). Induced current arrives at these sites via a surrounding ionic medium.
- E induced electromagnetic field
- Induced current arrives at these sites via a surrounding ionic medium.
- the presence of cells in a current pathway causes an induced current (“J”) to decay more rapidly with time (“J(t)”). This is due to an added electrical impedance of cells from membrane capacitance and time constants of
- the characteristic time constant of this pathway is determined by ion binding kinetics.
- Induced E from a PEMF or PRF signal can cause current to flow into an ion binding pathway and affect the number of Ca 2+ ions bound per unit time.
- An electrical equivalent of this is a change in voltage across the equivalent binding capacitance C ion , which is a direct measure of the change in electrical charge stored by C ion .
- Electrical charge is directly proportional to a surface concentration of Ca 2+ ions in the binding site, that is storage of charge is equivalent to storage of ions or other charged species on cell surfaces and junctions.
- Electrical impedance measurements, as well as direct kinetic analyses of binding rate constants provide values for time constants necessary for configuration of a PMF waveform to match a bandpass of target pathway structures. This allows for a required range of frequencies for any given induced E waveform for optimal coupling to target impedance, such as bandpass.
- Ion binding to regulatory molecules is a frequent EMF target, for example Ca 2+ binding to calmodulin (“CaM”).
- CaM calmodulin
- Use of this pathway is based upon acceleration of wound repair, for example bone repair, that involves modulation of growth factors released in various stages of repair.
- Growth factors such as platelet derived growth factor (“PDGF”), fibroblast growth factor (“FGF”), and epidermal growth factor (“EGF”) are all involved at an appropriate stage of healing.
- Angiogenesis is also integral to wound repair and modulated by PMF. All of these factors are Ca/CaM-dependent.
- a waveform can be configured for which induced power is sufficiently above background thermal noise power. Under correct physiological conditions, this waveform can have a physiologically significant bioeffect.
- a mathematical model can be configured to assimilate that thermal noise is present in all voltage dependent processes and represents a minimum threshold requirement to establish adequate SNR.
- Power spectral density, S n ( ⁇ ), of thermal noise can be expressed as:
- Z M (x, ⁇ ) is electrical impedance of a target pathway structure
- x is a dimension of a target pathway structure
- Re denotes a real part of impedance of a target pathway structure
- is maximum amplitude of voltage at each frequency as delivered by a chosen waveform to the target pathway structure.
- FIG. 1 is a flow diagram of a method for delivering electromagnetic signals to target pathway structures such as molecules, cells, tissue and organs of plants, animals, and humans for therapeutic and prophylactic purposes according to an embodiment of the present invention.
- a mathematical model having at least one waveform parameter is applied to configure at least one waveform to be coupled to a target pathway structure such as a molecule, cell, tissue, and organ (Step 101 ).
- the configured waveform satisfies a SNR or Power SNR model so that for a given and known target pathway structure it is possible to choose at least one waveform parameter so that a waveform is detectable in the target pathway structure above its background activity (Step 102 ) such as baseline thermal fluctuations in voltage and electrical impedance at a target pathway structure that depend upon a state of a cell and tissue, that is whether the state is at least one of resting, growing, replacing, and responding to injury.
- a SNR or Power SNR model so that for a given and known target pathway structure it is possible to choose at least one waveform parameter so that a waveform is detectable in the target pathway structure above its background activity (Step 102 ) such as baseline thermal fluctuations in voltage and electrical impedance at a target pathway structure that depend upon a state of a cell and tissue, that is whether the state is at least one of resting, growing, replacing, and responding to injury.
- a preferred embodiment of a generated electromagnetic signal is comprised of a burst of arbitrary waveforms having at least one waveform parameter that includes a plurality of frequency components ranging from about 0.01 Hz to about 100 MHz wherein the plurality of frequency components satisfies a Power SNR model (Step 102 ).
- a repetitive electromagnetic signal can be generated for example inductively or capacitively, from said configured at least one waveform (Step 103 ).
- the electromagnetic signal is coupled to a target pathway structure such as a molecule, cell, tissue, and organ by output of a coupling device such as an electrode or an inductor, placed in close proximity to the target pathway structure (Step 104 ).
- the coupling enhances a stimulus to which cells and tissues react in a physiologically meaningful manner.
- FIG. 2 illustrates a preferred embodiment of an apparatus according to the present invention.
- a miniature control circuit 201 is coupled to an end of at least one connector 202 such as wire. The opposite end of the at least one connector is coupled to a generating device such as a pair of electrical coils 203 .
- the miniature control circuit 201 is constructed in a manner that applies a mathematical model that is used to configure waveforms.
- the configured waveforms have to satisfy a SNR or Power SNR model so that for a given and known target pathway structure, it is possible to choose waveform parameters that satisfy SNR or Power SNR so that a waveform is detectable in the target pathway structure above its background activity.
- a waveform configured using a preferred embodiment according to the present invention may be applied to a target pathway structure such as a molecule, cell, tissue, and organ for a preferred total exposure time of under 1 minute to 240 minutes daily.
- Waveforms configured by the miniature control circuit 201 are directed to a generating device 203 such as electrical coils via connector 202 .
- the generating device 203 delivers a pulsing magnetic field configured according to a mathematical model, that can be used to provide treatment to a target pathway structure such as knee joint 204 .
- the miniature control circuit applies a pulsing magnetic field for a prescribed time and can automatically repeat applying the pulsing magnetic field for as many applications as are needed in a given time period, for example 10 times a day.
- a preferred embodiment according to the present invention can be positioned to treat the knee joint 204 by a positioning device.
- the positioning device can be portable such as an anatomical support, and is further described below with reference to FIG. 6 .
- Coupling a pulsing magnetic field to a target pathway structure such as a molecule, cell, tissue, and organ, therapeutically and prophylactically reduces inflammation thereby reducing pain and promotes healing.
- a target pathway structure such as a molecule, cell, tissue, and organ
- the electrical coils can be powered with a time varying magnetic field that induces a time varying electric field in a target pathway structure according to Faraday's law.
- An electromagnetic signal generated by the generating device 203 can also be applied using electrochemical coupling, wherein electrodes are in direct contact with skin or another outer electrically conductive boundary of a target pathway structure.
- the electromagnetic signal generated by the generating device 203 can also be applied using electrostatic coupling wherein an air gap exists between a generating device 203 such as an electrode and a target pathway structure such as a molecule, cell, tissue, and organ.
- a generating device 203 such as an electrode
- a target pathway structure such as a molecule, cell, tissue, and organ.
- FIG. 3 depicts a block diagram of a preferred embodiment according to the present invention of a miniature control circuit 300 .
- the miniature control circuit 300 produces waveforms that drive a generating device such as wire coils described above in FIG. 2 .
- the miniature control circuit can be activated by any activation means such as an on/off switch.
- the miniature control circuit 300 has a power source such as a lithium battery 301 .
- a preferred embodiment of the power source has an output voltage of 3.3 V but other voltages can be used.
- the power source can be an external power source such as an electric current outlet such as an AC/DC outlet, coupled to the present invention for example by a plug and wire.
- a switching power supply 302 controls voltage to a micro-controller 303 .
- a preferred embodiment of the micro-controller 303 uses an 8 bit 4 MHz micro-controller 303 but other bit MHz combination micro-controllers may be used.
- the switching power supply 302 also delivers current to storage capacitors 304 .
- a preferred embodiment of the present invention uses storage capacitors having a 220 uF output but other outputs can be used.
- the storage capacitors 304 allow high frequency pulses to be delivered to a coupling device such as inductors (Not Shown).
- the micro-controller 303 also controls a pulse shaper 305 and a pulse phase timing control 306 .
- the pulse shaper 305 and pulse phase timing control 306 determine pulse shape, burst width, burst envelope shape, and burst repetition rate.
- An integral waveform generator such as a sine wave or arbitrary number generator can also be incorporated to provide specific waveforms.
- a voltage level conversion sub-circuit 308 controls an induced field delivered to a target pathway structure.
- a switching Hexfet 308 allows pulses of randomized amplitude to be delivered to output 309 that routes a waveform to at least one coupling device such as an inductor.
- the micro-controller 303 can also control total exposure time of a single treatment of a target pathway structure such as a molecule, cell, tissue, and organ.
- the miniature control circuit 300 can be constructed to apply a pulsing magnetic field for a prescribed time and to automatically repeat applying the pulsing magnetic field for as many applications as are needed in a given time period, for example 10 times a day.
- a preferred embodiment according to the present invention uses treatments times of about 10 minutes to about 30 minutes.
- the coupling device 400 can be an electric coil 401 wound with multistrand flexible magnetic wire 402 .
- the multistrand flexible magnetic wire 402 enables the electric coil 401 to conform to specific anatomical configurations such as a limb or joint of a human or animal.
- a preferred embodiment of the electric coil 401 comprises about 10 to about 50 turns of about 0.01 mm to about 0.1 mm diameter multistrand magnet wire wound on an initially circular form having an outer diameter between about 2.5 cm and about 50 cm but other numbers of turns and wire diameters can be used.
- a preferred embodiment of the electric coil 401 can be encased with a non-toxic PVC mould 403 but other non-toxic moulds can also be used.
- a pulse 501 is repeated within a burst 502 that has a finite duration 503 .
- the duration 503 is such that a duty cycle which can be defined as a ratio of burst duration to signal period is between about 1 to about 10 ⁇ 5 .
- a preferred embodiment according to the present invention utilizes pseudo rectangular 10 microsecond pulses for pulse 501 applied in a burst 502 for about 10 to about 50 msec having a modified 1/f amplitude envelope 504 and with a finite duration 503 corresponding to a burst period of between about 0.1 and about 10 seconds.
- FIG. 6 illustrates a preferred embodiment according to the present invention of a positioning device such as a wrist support.
- a positioning device 600 such as a wrist support 601 is worn on a human wrist 602 .
- the positioning device can be constructed to be portable, can be constructed to be disposable, and can be constructed to be implantable.
- the positioning device can be used in combination with the present invention in a plurality of ways, for example incorporating the present invention into the positioning device for example by stitching, affixing the present invention onto the positioning device for example by Velcro®, and holding the present invention in place by constructing the positioning device to be elastic.
- the present invention can be constructed as a stand-alone device of any size with or without a positioning device, to be used anywhere for example at home, at a clinic, at a treatment center, and outdoors.
- the wrist support 601 can be made with any anatomical and support material, such as neoprene.
- Coils 603 are integrated into the wrist support 601 such that a signal configured according to the present invention, for example the waveform depicted in FIG. 5 , is applied from a dorsal portion that is the top of the wrist to a plantar portion that is the bottom of the wrist.
- Micro-circuitry 604 is attached to the exterior of the wrist support 601 using a fastening device such as Velcro® (Not Shown).
- the micro-circuitry is coupled to one end of at least one connecting device such as a flexible wire 605 .
- the other end of the at least one connecting device is coupled to the coils 603 .
- Other embodiments according to the present invention of the positioning device include knee, elbow, lower back, shoulder, other anatomical wraps, and apparel such as garments, fashion accessories, and footwear.
- the Power SNR approach for PMF signal configuration has been tested experimentally on calcium dependent myosin phosphorylation in a standard enzyme assay.
- the cell-free reaction mixture was chosen for phosphorylation rate to be linear in time for several minutes, and for sub-saturation Ca 2+ concentration. This opens the biological window for Ca 2+ /CaM to be EMF-sensitive. This system is not responsive to PMF at levels utilized in this study if Ca 2+ is at saturation levels with respect to CaM, and reaction is not slowed to a minute time range.
- MLC myosin light chain
- MLCK myosin light chain kinase
- a reaction mixture consisted of a basic solution containing 40 mM Hepes buffer, pH 7.0; 0.5 mM magnesium acetate; 1 mg/ml bovine serum albumin, 0.1% (w/v) Tween80; and 1 mM EGTA12. Free Ca 2+ was varied in the 1-7 ⁇ M range. Once Ca 2+ buffering was established, freshly prepared 70 nM CaM, 160 nM MLC and 2 nM MLCK were added to the basic solution to form a final reaction mixture. The low MLC/MLCK ratio allowed linear time behavior in the minute time range. This provided reproducible enzyme activities and minimized pipetting time errors.
- reaction mixture was freshly prepared daily for each series of experiments and was aliquoted in 100 ⁇ L portions into 1.5 ml Eppendorf tubes. All Eppendorf tubes containing reaction mixture were kept at 0° C. then transferred to a specially designed water bath maintained at 37 ⁇ 0.1° C. by constant perfusion of water prewarmed by passage through a Fisher Scientific model 900 heat exchanger. Temperature was monitored with a thermistor probe such as a Cole-Parmer model 8110-20, immersed in one Eppendorf tube during all experiments. Reaction was initiated with 2.5 ⁇ M 32P ATP, and was stopped with Laemmli Sample Buffer solution containing 30 ⁇ M EDTA. A minimum of five blank samples were counted in each experiment.
- Blanks comprised a total assay mixture minus one of the active components Ca 2+ , CaM, MLC or MLCK. Experiments for which blank counts were higher than 300 cpm were rejected. Phosphorylation was allowed to proceed for 5 min and was evaluated by counting 32P incorporated in MLC using a TM Analytic model 5303 Mark V liquid scintillation counter.
- the signal comprised repetitive bursts of a high frequency waveform. Amplitude was maintained constant at 0.2 G and repetition rate was 1 burst/sec for all exposures. Burst duration varied from 65 ⁇ sec to 1000 ⁇ sec based upon projections of Power SNR analysis which showed that optimal Power SNR would be achieved as burst duration approached 500 ⁇ sec.
- FIG. 7 wherein burst width 701 in ⁇ sec is plotted on the x-axis and Myosin Phosphorylation 702 as treated/sham is plotted on the y-axis. It can be seen that the PMF effect on Ca 2+ binding to CaM approaches its maximum at approximately 500 ⁇ sec, just as illustrated by the Power SNR model.
- a Power SNR model was further verified in an in vivo wound repair model.
- a rat wound model has been well characterized both biomechanically and biochemically, and was used in this study. Healthy, young adult male Sprague Dawley rats weighing more than 300 grams were utilized.
- the animals were anesthetized with an intraperitoneal dose of Ketamine 75 mg/kg and Medetomidine 0.5 mg/kg. After adequate anesthesia had been achieved, the dorsum was shaved, prepped with a dilute betadine/alcohol solution, and draped using sterile technique. Using a #10 scalpel, an 8-cm linear incision was performed through the skin down to the fascia on the dorsum of each rat. The wound edges were bluntly dissected to break any remaining dermal fibers, leaving an open wound approximately 4 cm in diameter. Hemostasis was obtained with applied pressure to avoid any damage to the skin edges. The skin edges were then closed with a 4-0 Ethilon running suture. Post-operatively, the animals received Buprenorphine 0.1-0.5 mg/kg, intraperitoneal. They were placed in individual cages and received food and water ad libitum.
- PMF exposure comprised two pulsed radio frequency waveforms.
- the first was a standard clinical PRF signal comprising a 65 ⁇ sec burst of 27.12 MHz sinusoidal waves at 1 Gauss amplitude and repeating at 600 bursts/sec.
- the second was a PRF signal reconfigured according to an embodiment of the present invention. For this signal burst duration was increased to 2000 ⁇ sec and the amplitude and repetition rate were reduced to 0.2 G and 5 bursts/sec respectively. PRF was applied for 30 minutes twice daily.
- Tensile strength was performed immediately after wound excision. Two 1 cm width strips of skin were transected perpendicular to the scar from each sample and used to measure the tensile strength in kg/mm 2 . The strips were excised from the same area in each rat to assure consistency of measurement. The strips were then mounted on a tensiometer. The strips were loaded at 10 mm/min and the maximum force generated before the wound pulled apart was recorded. The final tensile strength for comparison was determined by taking the average of the maximum load in kilograms per mm 2 of the two strips from the same wound.
- the average tensile strength for the 2000 ⁇ sec 0.2 Gauss PRF signal, configured according to an embodiment of the present invention using a Power SNR model was 21.2 ⁇ 5.6 kg/mm 2 for the treated group versus 13.7 ⁇ 4.1 kg/mm 2 (p ⁇ 0.01) for the control group, which is a 54% increase.
- Jurkat cells react to PMF stimulation of a T-cell receptor with cell cycle arrest and thus behave like normal T-lymphocytes stimulated by antigens at the T-cell receptor such as anti-CD3.
- results have shown both 60 Hz and PEMF fields decrease DNA synthesis of Jurkat cells, as is expected since PMF interacts with the T-cell receptor in the absence of a costimulatory signal. This is consistent with an anti-inflammatory response, as has been observed in clinical applications of PMF stimuli.
- the PEMF signal is more effective.
- a dosimetry analysis performed according to an embodiment of the present invention demonstrates why both signals are effective and why PEMF signals have a greater effect than 60 Hz signals on Jurkat cells in the most EMF-sensitive growth stage.
- Comparison of dosimetry from the two signals employed involves evaluation of the ratio of the Power spectrum of the thermal noise voltage that is Power SNR, to that of the induced voltage at the EMF-sensitive target pathway structure.
- the target pathway structure used is ion binding at receptor sites on Jurkat cells suspended in 2 mm of culture medium.
- FIG. 8 is a graph of results wherein Induced Field Frequency 801 in Hz is plotted on the x-axis and Power SNR 802 is plotted on the y-axis.
- FIG. 8 illustrates that both signals have sufficient Power spectrum that is Power SNR ⁇ 1, to be detected within a frequency range of binding kinetics.
- maximum Power SNR for the PEMF signal is significantly higher than that for the 60 Hz signal. This is because a PEMF signal has many frequency components falling within the bandpass of the binding pathway.
- the single frequency component of a 60 Hz signal lies at the mid-point of the bandpass of the target pathway.
- the Power SNR calculation that was used in this example is dependant upon ⁇ ion which is obtained from the rate constant for ion binding.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/003,108, filed Dec. 3, 2004 entitled “APPARATUS AND METHOD FOR ELECTROMAGNETIC TREATMENT OF PLANT, ANIMAL, AND HUMAN TISSUE, ORGANS, CELLS, AND MOLECULES which claims the benefit under 35 U.S.C. §119 of U.S. Provisional Patent Application No. 60/527,327, filed Dec. 5, 2003, titled “APPARATUS AND METHOD FOR ELECTROMAGNETIC TREATMENT OF PLANT, ANIMAL, AND HUMAN TISSUE, ORGANS, CELLS AND MOLECULES”.
- All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- 1. Field of the Invention
- This invention pertains generally to an apparatus and a method for in vitro and in vivo therapeutic and prophylactic treatment of plant, animal, and human tissue, organs, cells and molecules. In particular, an embodiment according to the present invention pertains to use of non-thermal time-varying magnetic fields configured for optimal coupling to target pathway structures such as molecules, cells, tissue, and organs, using power and amplitude comparison analysis to evaluate a signal to thermal noise ratio (“SNR”) in the target pathway structure. Another embodiment according to the present invention pertains to application of bursts of arbitrary waveform electromagnetic signals to target pathway structures such as molecules, cells, tissues, and organs using ultra lightweight portable coupling devices such as inductors and electrodes, and driver circuitry that can be incorporated into a positioning device such as knee, elbow, lower back, shoulder, foot, and other anatomical wraps, as well as apparel such as garments, footwear, and fashion accessories.
- Yet another embodiment according to the present invention pertains to application of steady state periodic signals of arbitrary waveform electromagnetic signals to target pathway structures such as molecules, cells, tissues, and organs. Examples of therapeutic and prophylactic applications of the present invention are musculoskeletal pain relief, edema reduction, increased local blood flow, microvascular blood perfusion, wound repair, bone repair, osteoporosis treatment and prevention, angiogenesis, neovascularization, enhanced immune response, tissue repair, enhanced transudation, and enhanced effectiveness of pharmacological agents. An embodiment according to the present invention can also be used in conjunction with other therapeutic and prophylactic procedures and modalities such as heat, cold, ultrasound, vacuum assisted wound closure, wound dressing, orthopedic fixation devices, and surgical interventions.
- 2. Discussion of Related Art
- It is now well established that application of weak non-thermal electromagnetic fields (“EMF”) can result in physiologically meaningful in vivo and in vitro bioeffects. Time-varying electromagnetic fields, comprising rectangular waveforms such as pulsing electromagnetic fields (“PEMF”), and sinusoidal waveforms such as pulsed radio frequency fields (“PRF”) ranging from several Hertz to an about 15 to an about 40 MHz range, are clinically beneficial when used as an adjunctive therapy for a variety of musculoskeletal injuries and conditions.
- Beginning in the 1960's, development of modern therapeutic and prophylactic devices was stimulated by clinical problems associated with non-union and delayed union bone fractures. Early work showed that an electrical pathway can be a means through which bone adaptively responds to mechanical input. Early therapeutic devices used implanted and semi-invasive electrodes delivering direct current (“DC”) to a fracture site. Non-invasive technologies were subsequently developed using electrical and electromagnetic fields. These modalities were originally created to provide a non-invasive “no-touch” means of inducing an electrical/mechanical waveform at a cell/tissue level. Clinical applications of these technologies in orthopaedics have led to approved applications by regulatory bodies worldwide for treatment of fractures such as non-unions and fresh fractures, as well as spine fusion. Presently several EMF devices constitute the standard armamentarium of orthopaedic clinical practice for treatment of difficult to heal fractures. The success rate for these devices has been very high. The database for this indication is large enough to enable its recommended use as a safe, non-surgical, non-invasive alternative to a first bone graft. Additional clinical indications for these technologies have been reported in double blind studies for treatment of avascular necrosis, tendinitis, osteoarthritis, wound repair, blood circulation and pain from arthritis as well as other musculoskeletal injuries.
- Cellular studies have addressed effects of weak low frequency electromagnetic fields on both signal transduction pathways and growth factor synthesis. It can be shown that EMF stimulates secretion of growth factors after a short, trigger-like duration. Ion/ligand binding processes at a cell membrane are generally considered an initial EMF target pathway structure. The clinical relevance to treatments for example of bone repair, is upregulation such as modulation, of growth factor production as part of normal molecular regulation of bone repair. Cellular level studies have shown effects on calcium ion transport, cell proliferation, Insulin Growth Factor (“IGF-II”) release, and IGF-II receptor expression in osteoblasts. Effects on Insulin Growth Factor-I (“IGF-I”) and IGF-II have also been demonstrated in rat fracture callus. Stimulation of transforming growth factor beta (“TGF-β”) messenger RNA (“mRNA”) with PEMF in a bone induction model in a rat has been shown. Studies have also demonstrated upregulation of TGF-β mRNA by PEMF in human osteoblast-like cell line designated MG-63, wherein there were increases in TGF-β1, collagen, and osteocalcin synthesis. PEMF stimulated an increase in TGF-β1 in both hypertrophic and atrophic cells from human non-union tissue. Further studies demonstrated an increase in both TGF-β1 mRNA and protein in osteoblast cultures resulting from a direct effect of EMF on a calcium/calmodulin-dependent pathway. Cartilage cell studies have shown similar increases in TGF-β1 mRNA and protein synthesis from EMF, demonstrating a therapeutic application to joint repair. U.S. Pat. No. 4,315,503 (1982) to Ryaby and U.S. Pat. No. 5,723,001 (1998) to Pilla typify the research conducted in this field.
- However, prior art in this field applies unnecessarily high amplitude and power to a target pathway structure, requires unnecessarily long treatment time, and is not portable.
- Therefore, a need exists for an apparatus and a method that more effectively modulates biochemical processes that regulate tissue growth and repair, shortens treatment times, and incorporates miniaturized circuitry and light weight applicators thus allowing the apparatus to be portable and if desired disposable. A further need exists for an apparatus and method that more effectively modulates biochemical processes that regulate tissue growth and repair, shortens treatment times, and incorporates miniaturized circuitry and light weight applicators that can be constructed to be implantable.
- An apparatus and a method for delivering electromagnetic signals to human, animal and plant target pathway structures such as molecules, cells, tissue and organs for therapeutic and prophylactic purposes. A preferred embodiment according to the present invention utilizes a Power Signal to Noise Ratio (“Power SNR”) approach to configure bioeffective waveforms and incorporates miniaturized circuitry and lightweight flexible coils. This advantageously allows a device that utilizes a Power SNR approach, miniaturized circuitry, and lightweight flexible coils, to be completely portable and if desired to be constructed as disposable and if further desired to be constructed as implantable.
- Specifically, broad spectral density bursts of electromagnetic waveforms, configured to achieve maximum signal power within a bandpass of a biological target, are selectively applied to target pathway structures such as living organs, tissues, cells and molecules. Waveforms are selected using a unique amplitude/power comparison with that of thermal noise in a target pathway structure. Signals comprise bursts of at least one of sinusoidal, rectangular, chaotic and random wave shapes, have frequency content in a range of about 0.01 Hz to about 100 MHz at about 1 to about 100,000 bursts per second, and have a burst repetition rate from about 0.01 to about 1000 bursts/second. Peak signal amplitude at a target pathway structure such as tissue, lies in a range of about 1 μV/cm to about 100 mV/cm. Each signal burst envelope may be a random function providing a means to accommodate different electromagnetic characteristics of healing tissue. A preferred embodiment according to the present comprises a 20 millisecond pulse burst comprising about 5 to about 20 microsecond symmetrical or asymmetrical pulses repeating at about 1 to about 100 kilohertz within the burst. The burst envelope is a modified 1/f function and is applied at random repetition rates. A resulting waveform can be delivered via inductive or capacitive coupling.
- It is an object of the present invention to configure a power spectrum of a waveform by mathematical simulation by using signal to noise ratio (“SNR”) analysis to configure an optimized, bioeffective waveform then coupling the configured waveform using a generating device such as ultra lightweight wire coils that are powered by a waveform configuration device such as miniaturized electronic circuitry.
- It is another object of the present invention to evaluate Power SNR for any target pathway structure such as molecules, cells, tissues and organs of plants, animals and humans using any input waveform, even if the electrical equivalents are non-linear as in a Hodgkin-Huxley membrane model.
- It is another object of the present invention to provide a method and apparatus for treating plants, animals and humans using electromagnetic fields selected by optimizing a power spectrum of a waveform to be applied to a chosen biochemical target pathway structure such as a molecule, cell, tissue and organ of a plant, animal, and human.
- It is another object of the present invention to employ significantly lower peak amplitudes and shorter pulse duration. This can be accomplished by matching via Power SNR, a frequency range in a signal to frequency response and sensitivity of a target pathway structure such as a molecule, cell, tissue, and organ, of plants, animals and humans.
- The above and yet other objects and advantages of the present invention will become apparent from the hereinafter set forth Brief Description of the Drawings, Detailed Description of the Invention, and Claims appended herewith.
- Preferred embodiments of the present invention will be described below in more detail, with reference to the accompanying drawings:
-
FIG. 1 is a flow diagram of a method for electromagnetic treatment of plant, animal, and human target pathway structures such as tissue, organs, cells, and molecules according to an embodiment of the present invention; -
FIG. 2 is a view of control circuitry and electrical coils applied to a knee joint according to a preferred embodiment of the present invention; -
FIG. 3 is a block diagram of miniaturized circuitry according to a preferred embodiment of the present invention; -
FIG. 4A is a line drawing of a wire coil such as an inductor according to a preferred embodiment of the present invention; -
FIG. 4B is a line drawing of a flexible magnetic wire according to a preferred embodiment of the present invention; -
FIG. 5 depicts a waveform delivered to a target pathway structure such as a molecule, cell, tissue or organ according to a preferred embodiment of the present invention; -
FIG. 6 is a view of a positioning device such as a wrist support according to a preferred embodiment of the present invention; -
FIG. 7 is a graph illustrating maximally increased myosin phosphorylation for a PMRF signal configured according to an embodiment of the present invention; and -
FIG. 8 is a graph illustrating a power consumption comparison between a 60 Hz signal and a PEMF signal configured according to an embodiment of the present invention. - Induced time-varying currents from PEMF or PRF devices flow in a target pathway structure such as a molecule, cell, tissue, and organ, and it is these currents that are a stimulus to which cells and tissues can react in a physiologically meaningful manner. The electrical properties of a target pathway structure affect levels and distributions of induced current. Molecules, cells, tissue, and organs are all in an induced current pathway such as cells in a gap junction contact. Ion or ligand interactions at binding sites on macromolecules that may reside on a membrane surface are voltage dependent processes, that is electrochemical, that can respond to an induced electromagnetic field (“E”). Induced current arrives at these sites via a surrounding ionic medium. The presence of cells in a current pathway causes an induced current (“J”) to decay more rapidly with time (“J(t)”). This is due to an added electrical impedance of cells from membrane capacitance and time constants of binding and other voltage sensitive membrane processes such as membrane transport.
- Equivalent electrical circuit models representing various membrane and charged interface configurations have been derived. For example, in Calcium (“Ca2+”) binding, the change in concentration of bound Ca2+ at a binding site due to induced E may be described in a frequency domain by an impedance expression such as:
-
- which has the form of a series resistance-capacitance electrical equivalent circuit. Where ω is angular frequency defined as 2πf, where f is frequency, i=−11/2, Zb(ω) is the binding impedance, and Rion and Cion are equivalent binding resistance and capacitance of an ion binding pathway. The value of the equivalent binding time constant, τion=RionCion, is related to a ion binding rate constant, kb, via τion=RionCion=1/kb. Thus, the characteristic time constant of this pathway is determined by ion binding kinetics.
- Induced E from a PEMF or PRF signal can cause current to flow into an ion binding pathway and affect the number of Ca2+ ions bound per unit time. An electrical equivalent of this is a change in voltage across the equivalent binding capacitance Cion, which is a direct measure of the change in electrical charge stored by Cion. Electrical charge is directly proportional to a surface concentration of Ca2+ ions in the binding site, that is storage of charge is equivalent to storage of ions or other charged species on cell surfaces and junctions. Electrical impedance measurements, as well as direct kinetic analyses of binding rate constants, provide values for time constants necessary for configuration of a PMF waveform to match a bandpass of target pathway structures. This allows for a required range of frequencies for any given induced E waveform for optimal coupling to target impedance, such as bandpass.
- Ion binding to regulatory molecules is a frequent EMF target, for example Ca2+ binding to calmodulin (“CaM”). Use of this pathway is based upon acceleration of wound repair, for example bone repair, that involves modulation of growth factors released in various stages of repair. Growth factors such as platelet derived growth factor (“PDGF”), fibroblast growth factor (“FGF”), and epidermal growth factor (“EGF”) are all involved at an appropriate stage of healing. Angiogenesis is also integral to wound repair and modulated by PMF. All of these factors are Ca/CaM-dependent.
- Utilizing a Ca/CaM pathway a waveform can be configured for which induced power is sufficiently above background thermal noise power. Under correct physiological conditions, this waveform can have a physiologically significant bioeffect.
- Application of a Power SNR model to Ca/CaM requires knowledge of electrical equivalents of Ca2+ binding kinetics at CaM. Within first order binding kinetics, changes in concentration of bound Ca2+ at CaM binding sites over time may be characterized in a frequency domain by an equivalent binding time constant, τion=RionCion, where Rion and Cion are equivalent binding resistance and capacitance of the ion binding pathway. τion is related to a ion binding rate constant, kb, via τion=RionCion=1/kb. Published values for kb can then be employed in a cell array model to evaluate SNR by comparing voltage induced by a PRF signal to thermal fluctuations in voltage at a CaM binding site. Employing numerical values for PMF response, such as Vmax=6.5×10−7 sec−1, [Ca2+]=2.5 μM, KD=30 μM, [Ca2+CaM]=KD([Ca2+]+[CaM]), yields kb=665 sec−1 (τion=1.5 msec). Such a value for τion can be employed in an electrical equivalent circuit for ion binding while power SNR analysis can be performed for any waveform structure.
- According to an embodiment of the present invention a mathematical model can be configured to assimilate that thermal noise is present in all voltage dependent processes and represents a minimum threshold requirement to establish adequate SNR. Power spectral density, Sn(ω), of thermal noise can be expressed as:
-
S n(ω)=4kTRe[Z M(x,ω)] - where ZM(x, ω) is electrical impedance of a target pathway structure, x is a dimension of a target pathway structure and Re denotes a real part of impedance of a target pathway structure. ZM(x, ω) can be expressed as:
-
- This equation clearly shows that electrical impedance of the target pathway structure, and contributions from extracellular fluid resistance (“Re”), intracellular fluid resistance (“Ri”) and intermembrane resistance (“Rg”) which are electrically connected to a target pathway structure, all contribute to noise filtering.
- A typical approach to evaluation of SNR uses a single value of a root mean square (RMS) noise voltage. This is calculated by taking a square root of an integration of Sn(ω)=4kTRe [ZM(x, ω)] over all frequencies relevant to either complete membrane response, or to bandwidth of a target pathway structure. SNR can be expressed by a ratio:
-
- where |VM(ω)| is maximum amplitude of voltage at each frequency as delivered by a chosen waveform to the target pathway structure.
- Referring to
FIG. 1 , whereinFIG. 1 is a flow diagram of a method for delivering electromagnetic signals to target pathway structures such as molecules, cells, tissue and organs of plants, animals, and humans for therapeutic and prophylactic purposes according to an embodiment of the present invention. A mathematical model having at least one waveform parameter is applied to configure at least one waveform to be coupled to a target pathway structure such as a molecule, cell, tissue, and organ (Step 101). The configured waveform satisfies a SNR or Power SNR model so that for a given and known target pathway structure it is possible to choose at least one waveform parameter so that a waveform is detectable in the target pathway structure above its background activity (Step 102) such as baseline thermal fluctuations in voltage and electrical impedance at a target pathway structure that depend upon a state of a cell and tissue, that is whether the state is at least one of resting, growing, replacing, and responding to injury. A preferred embodiment of a generated electromagnetic signal is comprised of a burst of arbitrary waveforms having at least one waveform parameter that includes a plurality of frequency components ranging from about 0.01 Hz to about 100 MHz wherein the plurality of frequency components satisfies a Power SNR model (Step 102). A repetitive electromagnetic signal can be generated for example inductively or capacitively, from said configured at least one waveform (Step 103). The electromagnetic signal is coupled to a target pathway structure such as a molecule, cell, tissue, and organ by output of a coupling device such as an electrode or an inductor, placed in close proximity to the target pathway structure (Step 104). The coupling enhances a stimulus to which cells and tissues react in a physiologically meaningful manner. -
FIG. 2 illustrates a preferred embodiment of an apparatus according to the present invention. Aminiature control circuit 201 is coupled to an end of at least oneconnector 202 such as wire. The opposite end of the at least one connector is coupled to a generating device such as a pair ofelectrical coils 203. Theminiature control circuit 201 is constructed in a manner that applies a mathematical model that is used to configure waveforms. The configured waveforms have to satisfy a SNR or Power SNR model so that for a given and known target pathway structure, it is possible to choose waveform parameters that satisfy SNR or Power SNR so that a waveform is detectable in the target pathway structure above its background activity. A preferred embodiment according to the present invention applies a mathematical model to induce a time-varying magnetic field and a time-varying electric field in a target pathway structure such as a molecule, cell, tissue, and organ, comprising about 10 to about 100 msec bursts of about 1 to about 100 microsecond rectangular pulses repeating at about 0.1 to about 10 pulses per second. Peak amplitude of the induced electric field is between about 1 uV/cm and about 100 mV/cm, varied according to a modified 1/f function where f=frequency. A waveform configured using a preferred embodiment according to the present invention may be applied to a target pathway structure such as a molecule, cell, tissue, and organ for a preferred total exposure time of under 1 minute to 240 minutes daily. However other exposure times can be used. Waveforms configured by theminiature control circuit 201 are directed to agenerating device 203 such as electrical coils viaconnector 202. The generatingdevice 203 delivers a pulsing magnetic field configured according to a mathematical model, that can be used to provide treatment to a target pathway structure such asknee joint 204. The miniature control circuit applies a pulsing magnetic field for a prescribed time and can automatically repeat applying the pulsing magnetic field for as many applications as are needed in a given time period, for example 10 times a day. A preferred embodiment according to the present invention can be positioned to treat the knee joint 204 by a positioning device. The positioning device can be portable such as an anatomical support, and is further described below with reference toFIG. 6 . Coupling a pulsing magnetic field to a target pathway structure such as a molecule, cell, tissue, and organ, therapeutically and prophylactically reduces inflammation thereby reducing pain and promotes healing. When electrical coils are used as thegenerating device 203, the electrical coils can be powered with a time varying magnetic field that induces a time varying electric field in a target pathway structure according to Faraday's law. An electromagnetic signal generated by the generatingdevice 203 can also be applied using electrochemical coupling, wherein electrodes are in direct contact with skin or another outer electrically conductive boundary of a target pathway structure. Yet in another embodiment according to the present invention, the electromagnetic signal generated by the generatingdevice 203 can also be applied using electrostatic coupling wherein an air gap exists between a generatingdevice 203 such as an electrode and a target pathway structure such as a molecule, cell, tissue, and organ. An advantage of the preferred embodiment according to the present invention is that its ultra lightweight coils and miniaturized circuitry allow for use with common physical therapy treatment modalities and at any body location for which pain relief and healing is desired. An advantageous result of application of the preferred embodiment according to the present invention is that a living organism's wellbeing can be maintained and enhanced. -
FIG. 3 depicts a block diagram of a preferred embodiment according to the present invention of aminiature control circuit 300. Theminiature control circuit 300 produces waveforms that drive a generating device such as wire coils described above inFIG. 2 . The miniature control circuit can be activated by any activation means such as an on/off switch. Theminiature control circuit 300 has a power source such as alithium battery 301. A preferred embodiment of the power source has an output voltage of 3.3 V but other voltages can be used. In another embodiment according to the present invention the power source can be an external power source such as an electric current outlet such as an AC/DC outlet, coupled to the present invention for example by a plug and wire. A switchingpower supply 302 controls voltage to amicro-controller 303. A preferred embodiment of the micro-controller 303 uses an 8 bit 4MHz micro-controller 303 but other bit MHz combination micro-controllers may be used. The switchingpower supply 302 also delivers current tostorage capacitors 304. A preferred embodiment of the present invention uses storage capacitors having a 220 uF output but other outputs can be used. Thestorage capacitors 304 allow high frequency pulses to be delivered to a coupling device such as inductors (Not Shown). Themicro-controller 303 also controls apulse shaper 305 and a pulsephase timing control 306. Thepulse shaper 305 and pulsephase timing control 306 determine pulse shape, burst width, burst envelope shape, and burst repetition rate. An integral waveform generator, such as a sine wave or arbitrary number generator can also be incorporated to provide specific waveforms. A voltagelevel conversion sub-circuit 308 controls an induced field delivered to a target pathway structure. A switchingHexfet 308 allows pulses of randomized amplitude to be delivered tooutput 309 that routes a waveform to at least one coupling device such as an inductor. Themicro-controller 303 can also control total exposure time of a single treatment of a target pathway structure such as a molecule, cell, tissue, and organ. Theminiature control circuit 300 can be constructed to apply a pulsing magnetic field for a prescribed time and to automatically repeat applying the pulsing magnetic field for as many applications as are needed in a given time period, for example 10 times a day. A preferred embodiment according to the present invention uses treatments times of about 10 minutes to about 30 minutes. - Referring to
FIGS. 4A and 4B a preferred embodiment according to the present invention of acoupling device 400 such as an inductor is shown. Thecoupling device 400 can be anelectric coil 401 wound with multistrand flexiblemagnetic wire 402. The multistrand flexiblemagnetic wire 402 enables theelectric coil 401 to conform to specific anatomical configurations such as a limb or joint of a human or animal. A preferred embodiment of theelectric coil 401 comprises about 10 to about 50 turns of about 0.01 mm to about 0.1 mm diameter multistrand magnet wire wound on an initially circular form having an outer diameter between about 2.5 cm and about 50 cm but other numbers of turns and wire diameters can be used. A preferred embodiment of theelectric coil 401 can be encased with anon-toxic PVC mould 403 but other non-toxic moulds can also be used. - Referring to
FIG. 5 an embodiment according to the present invention of awaveform 500 is illustrated. Apulse 501 is repeated within aburst 502 that has afinite duration 503. Theduration 503 is such that a duty cycle which can be defined as a ratio of burst duration to signal period is between about 1 to about 10−5. A preferred embodiment according to the present invention utilizes pseudo rectangular 10 microsecond pulses forpulse 501 applied in aburst 502 for about 10 to about 50 msec having a modified 1/f amplitude envelope 504 and with afinite duration 503 corresponding to a burst period of between about 0.1 and about 10 seconds. -
FIG. 6 illustrates a preferred embodiment according to the present invention of a positioning device such as a wrist support. Apositioning device 600 such as awrist support 601 is worn on ahuman wrist 602. The positioning device can be constructed to be portable, can be constructed to be disposable, and can be constructed to be implantable. The positioning device can be used in combination with the present invention in a plurality of ways, for example incorporating the present invention into the positioning device for example by stitching, affixing the present invention onto the positioning device for example by Velcro®, and holding the present invention in place by constructing the positioning device to be elastic. - In another embodiment according to the present invention, the present invention can be constructed as a stand-alone device of any size with or without a positioning device, to be used anywhere for example at home, at a clinic, at a treatment center, and outdoors. The
wrist support 601 can be made with any anatomical and support material, such as neoprene.Coils 603 are integrated into thewrist support 601 such that a signal configured according to the present invention, for example the waveform depicted inFIG. 5 , is applied from a dorsal portion that is the top of the wrist to a plantar portion that is the bottom of the wrist.Micro-circuitry 604 is attached to the exterior of thewrist support 601 using a fastening device such as Velcro® (Not Shown). The micro-circuitry is coupled to one end of at least one connecting device such as aflexible wire 605. The other end of the at least one connecting device is coupled to thecoils 603. Other embodiments according to the present invention of the positioning device include knee, elbow, lower back, shoulder, other anatomical wraps, and apparel such as garments, fashion accessories, and footwear. - The Power SNR approach for PMF signal configuration has been tested experimentally on calcium dependent myosin phosphorylation in a standard enzyme assay. The cell-free reaction mixture was chosen for phosphorylation rate to be linear in time for several minutes, and for sub-saturation Ca2+ concentration. This opens the biological window for Ca2+/CaM to be EMF-sensitive. This system is not responsive to PMF at levels utilized in this study if Ca2+ is at saturation levels with respect to CaM, and reaction is not slowed to a minute time range. Experiments were performed using myosin light chain (“MLC”) and myosin light chain kinase (“MLCK”) isolated from turkey gizzard. A reaction mixture consisted of a basic solution containing 40 mM Hepes buffer, pH 7.0; 0.5 mM magnesium acetate; 1 mg/ml bovine serum albumin, 0.1% (w/v) Tween80; and 1 mM EGTA12. Free Ca2+ was varied in the 1-7 μM range. Once Ca2+ buffering was established, freshly prepared 70 nM CaM, 160 nM MLC and 2 nM MLCK were added to the basic solution to form a final reaction mixture. The low MLC/MLCK ratio allowed linear time behavior in the minute time range. This provided reproducible enzyme activities and minimized pipetting time errors.
- The reaction mixture was freshly prepared daily for each series of experiments and was aliquoted in 100 μL portions into 1.5 ml Eppendorf tubes. All Eppendorf tubes containing reaction mixture were kept at 0° C. then transferred to a specially designed water bath maintained at 37±0.1° C. by constant perfusion of water prewarmed by passage through a Fisher
Scientific model 900 heat exchanger. Temperature was monitored with a thermistor probe such as a Cole-Parmer model 8110-20, immersed in one Eppendorf tube during all experiments. Reaction was initiated with 2.5 μM 32P ATP, and was stopped with Laemmli Sample Buffer solution containing 30 μM EDTA. A minimum of five blank samples were counted in each experiment. Blanks comprised a total assay mixture minus one of the active components Ca2+, CaM, MLC or MLCK. Experiments for which blank counts were higher than 300 cpm were rejected. Phosphorylation was allowed to proceed for 5 min and was evaluated by counting 32P incorporated in MLC using a TM Analytic model 5303 Mark V liquid scintillation counter. - The signal comprised repetitive bursts of a high frequency waveform. Amplitude was maintained constant at 0.2 G and repetition rate was 1 burst/sec for all exposures. Burst duration varied from 65 μsec to 1000 μsec based upon projections of Power SNR analysis which showed that optimal Power SNR would be achieved as burst duration approached 500 μsec. The results are shown in
FIG. 7 whereinburst width 701 in μsec is plotted on the x-axis andMyosin Phosphorylation 702 as treated/sham is plotted on the y-axis. It can be seen that the PMF effect on Ca2+ binding to CaM approaches its maximum at approximately 500 μsec, just as illustrated by the Power SNR model. - These results confirm that a PMF signal, configured according to an embodiment of the present invention, would maximally increase myosin phosphorylation for burst durations sufficient to achieve optimal Power SNR for a given magnetic field amplitude.
- According to an embodiment of the present invention use of a Power SNR model was further verified in an in vivo wound repair model. A rat wound model has been well characterized both biomechanically and biochemically, and was used in this study. Healthy, young adult male Sprague Dawley rats weighing more than 300 grams were utilized.
- The animals were anesthetized with an intraperitoneal dose of Ketamine 75 mg/kg and Medetomidine 0.5 mg/kg. After adequate anesthesia had been achieved, the dorsum was shaved, prepped with a dilute betadine/alcohol solution, and draped using sterile technique. Using a #10 scalpel, an 8-cm linear incision was performed through the skin down to the fascia on the dorsum of each rat. The wound edges were bluntly dissected to break any remaining dermal fibers, leaving an open wound approximately 4 cm in diameter. Hemostasis was obtained with applied pressure to avoid any damage to the skin edges. The skin edges were then closed with a 4-0 Ethilon running suture. Post-operatively, the animals received Buprenorphine 0.1-0.5 mg/kg, intraperitoneal. They were placed in individual cages and received food and water ad libitum.
- PMF exposure comprised two pulsed radio frequency waveforms. The first was a standard clinical PRF signal comprising a 65 μsec burst of 27.12 MHz sinusoidal waves at 1 Gauss amplitude and repeating at 600 bursts/sec. The second was a PRF signal reconfigured according to an embodiment of the present invention. For this signal burst duration was increased to 2000 μsec and the amplitude and repetition rate were reduced to 0.2 G and 5 bursts/sec respectively. PRF was applied for 30 minutes twice daily.
- Tensile strength was performed immediately after wound excision. Two 1 cm width strips of skin were transected perpendicular to the scar from each sample and used to measure the tensile strength in kg/mm2. The strips were excised from the same area in each rat to assure consistency of measurement. The strips were then mounted on a tensiometer. The strips were loaded at 10 mm/min and the maximum force generated before the wound pulled apart was recorded. The final tensile strength for comparison was determined by taking the average of the maximum load in kilograms per mm2 of the two strips from the same wound.
- The results showed average tensile strength for the 65
μsec 1 Gauss PRF signal was 19.3±4.3 kg/mm2 for the exposed group versus 13.0±3.5 kg/mm2 for the control group (p<0.01), which is a 48% increase. In contrast, the average tensile strength for the 2000 μsec 0.2 Gauss PRF signal, configured according to an embodiment of the present invention using a Power SNR model was 21.2±5.6 kg/mm2 for the treated group versus 13.7±4.1 kg/mm2 (p<0.01) for the control group, which is a 54% increase. The results for the two signals were not significantly different from each other. - These results demonstrate that an embodiment of the present invention allowed a new PRF signal to be configured that could be produced with significantly lower power. The PRF signal configured according to an embodiment of the present invention, accelerated wound repair in the rat model in a low power manner versus that for a clinical PRF signal which accelerated wound repair but required more than two orders of magnitude more power to produce.
- In this example Jurkat cells react to PMF stimulation of a T-cell receptor with cell cycle arrest and thus behave like normal T-lymphocytes stimulated by antigens at the T-cell receptor such as anti-CD3. For example in bone healing, results have shown both 60 Hz and PEMF fields decrease DNA synthesis of Jurkat cells, as is expected since PMF interacts with the T-cell receptor in the absence of a costimulatory signal. This is consistent with an anti-inflammatory response, as has been observed in clinical applications of PMF stimuli. The PEMF signal is more effective. A dosimetry analysis performed according to an embodiment of the present invention demonstrates why both signals are effective and why PEMF signals have a greater effect than 60 Hz signals on Jurkat cells in the most EMF-sensitive growth stage.
- Comparison of dosimetry from the two signals employed involves evaluation of the ratio of the Power spectrum of the thermal noise voltage that is Power SNR, to that of the induced voltage at the EMF-sensitive target pathway structure. The target pathway structure used is ion binding at receptor sites on Jurkat cells suspended in 2 mm of culture medium. The average peak electric field at the binding site from a PEMF signal comprising 5 msec burst of 200 μsec pulses repeating at 15/sec, was 1 mV/cm, while for a 60 Hz signal it was 50 μV/cm.
-
FIG. 8 is a graph of results whereinInduced Field Frequency 801 in Hz is plotted on the x-axis andPower SNR 802 is plotted on the y-axis.FIG. 8 illustrates that both signals have sufficient Power spectrum that is Power SNR≈1, to be detected within a frequency range of binding kinetics. However, maximum Power SNR for the PEMF signal is significantly higher than that for the 60 Hz signal. This is because a PEMF signal has many frequency components falling within the bandpass of the binding pathway. The single frequency component of a 60 Hz signal lies at the mid-point of the bandpass of the target pathway. The Power SNR calculation that was used in this example is dependant upon τion which is obtained from the rate constant for ion binding. Had this calculation been performed a priori it would have concluded that both signals satisfied basic detectability requirements and could modulate an EMF-sensitive ion binding pathway at the start of a regulatory cascade for DNA synthesis in these cells. The previous examples illustrated that utilizing the rate constant for Ca/CaM binding could lead to successful projections for bioeffective EMF signals in a variety of systems. - Having described embodiments for an apparatus and a method for delivering electromagnetic treatment to human, animal and plant molecules, cells, tissue and organs, it is noted that modifications and variations can be made by persons skilled in the art in light of the above teachings. It is therefore to be understood that changes may be made in the particular embodiments of the invention disclosed which are within the scope and spirit of the invention as defined by the appended claims.
Claims (57)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/772,002 US20100222631A1 (en) | 2003-12-05 | 2010-04-30 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US12/819,956 US20110112352A1 (en) | 2003-12-05 | 2010-06-21 | Apparatus and method for electromagnetic treatment |
US13/080,450 US8961385B2 (en) | 2003-12-05 | 2011-04-05 | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US13/285,761 US9656096B2 (en) | 2003-12-05 | 2011-10-31 | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US13/801,789 US20130274540A1 (en) | 2003-12-05 | 2013-03-13 | Apparatus and method for electromagnetic treatment |
US14/058,973 US20140046117A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US14/171,553 US9440089B2 (en) | 2003-12-05 | 2014-02-03 | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
US14/171,613 US9433797B2 (en) | 2003-12-05 | 2014-02-03 | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
US14/171,644 US9415233B2 (en) | 2003-12-05 | 2014-02-03 | Apparatus and method for electromagnetic treatment of neurological pain |
US14/608,140 US10226640B2 (en) | 2003-12-05 | 2015-01-28 | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US14/687,716 US10207122B2 (en) | 2003-12-05 | 2015-04-15 | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US15/217,855 US10426967B2 (en) | 2003-12-05 | 2016-07-22 | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
US15/607,211 US20180104505A1 (en) | 2003-12-05 | 2017-05-26 | Apparatus and method for electromagnetic treatment |
US16/657,827 US20200094068A1 (en) | 2003-12-05 | 2019-10-18 | Method for treatment of non-alcoholic steatohepatitis using pulsed electromagnetic field therapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52732703P | 2003-12-05 | 2003-12-05 | |
US11/003,108 US7744524B2 (en) | 2003-12-05 | 2004-12-03 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US12/772,002 US20100222631A1 (en) | 2003-12-05 | 2010-04-30 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/003,108 Continuation US7744524B2 (en) | 2003-12-05 | 2004-12-03 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/819,956 Continuation-In-Part US20110112352A1 (en) | 2003-12-05 | 2010-06-21 | Apparatus and method for electromagnetic treatment |
US14/058,973 Division US20140046117A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100222631A1 true US20100222631A1 (en) | 2010-09-02 |
Family
ID=34680788
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/003,108 Active 2028-12-01 US7744524B2 (en) | 2003-12-05 | 2004-12-03 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US12/772,002 Abandoned US20100222631A1 (en) | 2003-12-05 | 2010-04-30 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US12/771,954 Abandoned US20100210893A1 (en) | 2003-12-05 | 2010-04-30 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US14/058,764 Abandoned US20140046115A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US14/058,973 Abandoned US20140046117A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US15/349,921 Abandoned US20170266458A1 (en) | 2003-12-05 | 2016-11-11 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/003,108 Active 2028-12-01 US7744524B2 (en) | 2003-12-05 | 2004-12-03 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/771,954 Abandoned US20100210893A1 (en) | 2003-12-05 | 2010-04-30 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US14/058,764 Abandoned US20140046115A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US14/058,973 Abandoned US20140046117A1 (en) | 2003-12-05 | 2013-10-21 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US15/349,921 Abandoned US20170266458A1 (en) | 2003-12-05 | 2016-11-11 | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
Country Status (9)
Country | Link |
---|---|
US (6) | US7744524B2 (en) |
EP (1) | EP1694409A2 (en) |
JP (1) | JP2007524476A (en) |
AU (1) | AU2004296198A1 (en) |
BR (1) | BRPI0417129A (en) |
CA (1) | CA2548270A1 (en) |
IL (1) | IL176126A0 (en) |
NZ (1) | NZ548283A (en) |
WO (1) | WO2005056111A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090132010A1 (en) * | 2007-11-19 | 2009-05-21 | Kronberg James W | System and method for generating complex bioelectric stimulation signals while conserving power |
US20110004261A1 (en) * | 2007-05-03 | 2011-01-06 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US8343027B1 (en) | 2012-01-30 | 2013-01-01 | Ivivi Health Sciences, Llc | Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant |
US8415123B2 (en) | 2004-04-19 | 2013-04-09 | Ivivi Health Sciences, Llc | Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells |
WO2013181144A1 (en) * | 2012-05-31 | 2013-12-05 | Rogachefsky Richard A | Applicable device for healing injuries with magnetic fields |
US8961385B2 (en) | 2003-12-05 | 2015-02-24 | Ivivi Health Sciences, Llc | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US9320913B2 (en) | 2014-04-16 | 2016-04-26 | Rio Grande Neurosciences, Inc. | Two-part pulsed electromagnetic field applicator for application of therapeutic energy |
US9415233B2 (en) | 2003-12-05 | 2016-08-16 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological pain |
US9427598B2 (en) | 2010-10-01 | 2016-08-30 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans |
US9433797B2 (en) | 2003-12-05 | 2016-09-06 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
US9440089B2 (en) | 2003-12-05 | 2016-09-13 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
US9656096B2 (en) | 2003-12-05 | 2017-05-23 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US9968797B2 (en) | 2007-05-03 | 2018-05-15 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US10335282B2 (en) | 2016-02-09 | 2019-07-02 | Richard A. Rogachefsky | Magnetic joint replacement |
US10350428B2 (en) | 2014-11-04 | 2019-07-16 | Endonovo Therapetics, Inc. | Method and apparatus for electromagnetic treatment of living systems |
US10806942B2 (en) | 2016-11-10 | 2020-10-20 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
US10870013B2 (en) | 2017-05-08 | 2020-12-22 | Aah Holdings Llc | Multi-coil electromagnetic apparatus |
US11071876B2 (en) | 2018-12-03 | 2021-07-27 | Aah Holdings Llc | Apparatus and method for treatment of mental and behavioral conditions and disorders with electromagnetic fields |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744524B2 (en) * | 2003-12-05 | 2010-06-29 | Ivivi Health Sciences, Llc | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US20130218235A9 (en) * | 2005-03-07 | 2013-08-22 | Arthur A. Pilla | Excessive fibrous capsule formation and capsular contracture apparatus and method for using same |
US7758490B2 (en) * | 2005-09-10 | 2010-07-20 | Ivivi Health Sciences, Llc | Integrated coil apparatus for therapeutically treating human and animal cells, tissues and organs with electromagnetic fields and method for using same |
US20110112352A1 (en) * | 2003-12-05 | 2011-05-12 | Pilla Arthur A | Apparatus and method for electromagnetic treatment |
US20070173904A1 (en) * | 2006-01-25 | 2007-07-26 | Pilla Arthur A | Self-contained electromagnetic apparatus for treatment of molecules, cells, tissues, and organs within a cerebrofacial area and method for using same |
US20060212077A1 (en) * | 2005-03-07 | 2006-09-21 | Pilla Arthur A | Electromagnetic treatment apparatus for augmenting wound repair and method for using same |
US20070026514A1 (en) * | 2005-03-07 | 2007-02-01 | Pilla Arthur A | Electromagnetic treatment apparatus for enhancing pharmacological, chemical, and topical agent effectiveness and method for using same |
EP1898991B1 (en) | 2005-05-04 | 2016-06-29 | Impulse Dynamics NV | Protein activity modification |
US7465269B2 (en) | 2005-07-14 | 2008-12-16 | Djo, Llc | Bone growth stimulator |
WO2008036383A1 (en) * | 2006-09-20 | 2008-03-27 | Ivivi Technologies, Inc. | Electromagnetic apparatus for respiratory disease and method for using same |
US20080097141A1 (en) * | 2006-10-19 | 2008-04-24 | Stanley Kolt | K-ring electromagnetic treatment apparatus, system and method for tumors, arthritis and other ailments |
EP2154240A1 (en) * | 2008-08-06 | 2010-02-17 | UToC B.V. i.o | PRF in cell and tissue culture |
US8460167B2 (en) * | 2009-09-14 | 2013-06-11 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
US8827886B2 (en) | 2009-09-14 | 2014-09-09 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
US8932196B2 (en) | 2009-09-14 | 2015-01-13 | Minnesota Medical Physics Llc | Thermally assisted pulsed electro-magnetic field stimulation device and method for treatment of osteoarthritis |
US20110137105A1 (en) * | 2009-12-07 | 2011-06-09 | Chih-Kuo Liang | Portable magnetic field stimulator |
EP2613846B1 (en) * | 2010-09-08 | 2022-05-11 | BioMagnetic Sciences, LLC | Thermally assisted pulsed electro-magnetic field stimulation devices for treatment of osteoarthritis |
US20120191018A1 (en) * | 2011-01-25 | 2012-07-26 | Willeford Kenneth L | Method and device for treating osteoarthritis noninvasively |
US8972019B2 (en) * | 2011-01-25 | 2015-03-03 | Kenneth L. Willeford | Method and device for treating osteoarthritis noninvasively |
AU2015202363B2 (en) * | 2011-01-25 | 2016-11-24 | Kenneth L. Willeford | Method and device for treating osteoarthritis noninvasively |
US20140249355A1 (en) * | 2011-10-20 | 2014-09-04 | Bioelectronics Corp. | Pulsed electromagnetic field device with adhesive applicator |
US20140303425A1 (en) * | 2011-11-04 | 2014-10-09 | Ivivi Health Sciences, Llc | Method and apparatus for electromagnetic treatment of cognition and neurological injury |
PL2822650T3 (en) * | 2012-03-05 | 2020-07-13 | Nexstim Oyj | Bi-phasic paired pulse transcranial magnetic stimulation |
CN105920738A (en) * | 2016-07-11 | 2016-09-07 | 林森 | Knee osteoarthritis disease therapeutic instrument |
US20200044318A1 (en) * | 2017-02-24 | 2020-02-06 | Andre' DiMino | Devices and Methods for the Delivery of Non-Thermal Therapeutic and Prophylactic Electromagnetic Fields from a Mobile Device |
EP3740275B1 (en) * | 2018-01-18 | 2023-12-20 | Pulsar Medtech Ltd. | External electronic patch for accelerating bone healing or regeneration after trauma |
US11850440B2 (en) * | 2019-08-22 | 2023-12-26 | University Of Iowa Research Foundation | Therapeutic systems using magnetic fields |
US10596384B2 (en) * | 2018-03-21 | 2020-03-24 | Garwood Medical Devices, Llc | Method and system for bone regeneration |
AU2019359880B2 (en) | 2018-10-18 | 2021-05-13 | Aah Holdings Llc | Inductive applicator coil arrangement for therapeutically treating human and animal bodies |
CN109300547B (en) * | 2018-10-19 | 2021-06-22 | 江西理工大学 | Method for researching state transition of heart Hodgkin-Huxley purkinje fiber model |
US11020603B2 (en) | 2019-05-06 | 2021-06-01 | Kamran Ansari | Systems and methods of modulating electrical impulses in an animal brain using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing |
US11517760B2 (en) | 2019-05-06 | 2022-12-06 | Kamran Ansari | Systems and methods of treating medical conditions using arrays of planar coils configured to generate pulsed electromagnetic fields and integrated into clothing |
CN111309795B (en) * | 2020-01-21 | 2023-05-05 | 北京百度网讯科技有限公司 | Business abnormality positioning method and device, electronic equipment and medium |
Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1233841A (en) * | 1914-05-12 | 1917-07-17 | Marconi Wireless Telegraph Co America | Means for receiving electrical oscillations. |
US2276996A (en) * | 1940-11-30 | 1942-03-17 | A J Ginsberg | Non-radio-interfering therapeutic apparatus |
US3043310A (en) * | 1959-04-24 | 1962-07-10 | Diapulse Mfg Corp Of America | Treatment head for athermapeutic apparatus |
US3181535A (en) * | 1957-10-04 | 1965-05-04 | Diapulse Mfg Corp Of America | Athermapeutic apparatus |
US3329149A (en) * | 1964-10-28 | 1967-07-04 | Dynapower Systems Corp Of Cali | Supporting arm for electrotherapeutic treatment head |
US3329148A (en) * | 1965-09-21 | 1967-07-04 | Dynapower Systems Corp Of Cali | Control of electrotherapeutic apparatus |
US3800802A (en) * | 1972-01-07 | 1974-04-02 | Int Medical Electronics Ltd | Short-wave therapy apparatus |
US3890953A (en) * | 1971-04-06 | 1975-06-24 | Werner Kraus | Electrical apparatus generating a low frequency, alternating magnetic field for promoting the growth of bone and other body tissues |
US3952751A (en) * | 1975-01-08 | 1976-04-27 | W. Denis Kendall | High-performance electrotherapeutic apparatus |
US4028518A (en) * | 1974-06-18 | 1977-06-07 | L'oreal | Device for superficially heating an adjacent body |
US4197851A (en) * | 1977-04-14 | 1980-04-15 | Fellus Victor M | Apparatus for emitting high-frequency electromagnetic waves |
US4266532A (en) * | 1976-11-17 | 1981-05-12 | Electro-Biology, Inc. | Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment |
US4315503A (en) * | 1976-11-17 | 1982-02-16 | Electro-Biology, Inc. | Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment |
US4338945A (en) * | 1978-03-03 | 1982-07-13 | Clinical Engineering Laboratory Limited | Method and randomized electrical stimulation system for pain relief |
US4340063A (en) * | 1980-01-02 | 1982-07-20 | Empi, Inc. | Stimulation device |
US4374482A (en) * | 1980-12-23 | 1983-02-22 | Norlin Industries, Inc. | Vocal effect for musical instrument |
US4428366A (en) * | 1981-05-06 | 1984-01-31 | Alfred B. Kurtz | Electromagnetic apparatus and method for the reduction of serum glucose levels |
US4454882A (en) * | 1981-07-29 | 1984-06-19 | Olympus Optical Co., Ltd. | Laser apparatus utilizing marking laser for triggering operative laser |
US4548208A (en) * | 1984-06-27 | 1985-10-22 | Medtronic, Inc. | Automatic adjusting induction coil treatment device |
US4556051A (en) * | 1982-11-05 | 1985-12-03 | Empi, Inc. | Method and apparatus for healing tissue |
US4654574A (en) * | 1983-06-29 | 1987-03-31 | Sheldon Thaler | Apparatus for reactively applying electrical energy pulses to a living body |
US4672951A (en) * | 1985-12-30 | 1987-06-16 | Bio-Electric, Inc. | Method and apparatus for treatment of biological tissue |
US4674482A (en) * | 1984-09-12 | 1987-06-23 | Irt, Inc. | Pulse electro-magnetic field therapy device with auto bias circuit |
US4829984A (en) * | 1983-12-15 | 1989-05-16 | Gordon Robert T | Method for the improvement of transplantation techniques and for the preservation of tissue |
US4850372A (en) * | 1987-08-25 | 1989-07-25 | The Johns Hopkins University | Electromagnetic non-invasive measurement and monitoring system for osteoporosis |
US4926881A (en) * | 1987-06-15 | 1990-05-22 | Matsushita Electric Works, Ltd. | Portable battery powered electromagnetic therapy applicator |
US4993413A (en) * | 1988-09-22 | 1991-02-19 | The Research Foundation Of State University Of New York | Method and apparatus for inducing a current and voltage in living tissue |
US4998532A (en) * | 1986-05-23 | 1991-03-12 | Lti Biomedical, Inc. | Portable electro-therapy system |
US5000178A (en) * | 1986-05-23 | 1991-03-19 | Lti Biomedical, Inc. | Shielded electromagnetic transducer |
US5014699A (en) * | 1986-05-23 | 1991-05-14 | Trustees Of The University Of Pennsylvania | Electromagnetic method and apparatus for healing living tissue |
US5123898A (en) * | 1988-03-23 | 1992-06-23 | Life Resonances, Inc. | Method and apparatus for controlling tissue growth with an applied fluctuating magnetic field |
US5147284A (en) * | 1989-08-17 | 1992-09-15 | Fedorov Svjatoslav N | Device and method for restoration of visual functions |
US5181902A (en) * | 1990-09-21 | 1993-01-26 | American Medical Electronics, Inc. | Double-transducer system for PEMF Therapy |
US5224922A (en) * | 1988-05-19 | 1993-07-06 | Kurtz Warren H | Quasistatic biological cell and tissue modifier |
US5338286A (en) * | 1992-12-08 | 1994-08-16 | Electro-Biology, Inc. | Electromagnetic bioresponse by selective spectral suppression in pulsed field stimulation |
US5386837A (en) * | 1993-02-01 | 1995-02-07 | Mmtc, Inc. | Method for enhancing delivery of chemotherapy employing high-frequency force fields |
US5407421A (en) * | 1994-05-18 | 1995-04-18 | Goldsmith; Seth | Compressive brace |
US5480373A (en) * | 1991-07-09 | 1996-01-02 | Dr. Fischer Aktiengesellschaft | Device for transporting ions, in particular, protons |
US5518496A (en) * | 1988-03-23 | 1996-05-21 | Life Resonances, Inc. | Deformable magnetic field aiding coils for use in controlling tissue growth |
US5529569A (en) * | 1987-09-08 | 1996-06-25 | Woo; Gilson | Treatment of ailments, afflections and diseases |
US5595564A (en) * | 1993-11-26 | 1997-01-21 | Biofarm S.R.L. | Device for retarding hair loss and for stimulating its regrowth |
US5718246A (en) * | 1996-01-03 | 1998-02-17 | Preferential, Inc. | Preferential induction of electrically mediated cell death from applied pulses |
US5718721A (en) * | 1996-12-23 | 1998-02-17 | Ross; Jesse | Method of relieving migraine headache pain |
US5723001A (en) * | 1994-06-09 | 1998-03-03 | Electropharmacology, Inc. | Apparatus and method for therapeutically treating human body tissue with electromagnetic radiation |
US5743844A (en) * | 1996-11-01 | 1998-04-28 | Amei Technologies, Inc. | High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system |
US5778894A (en) * | 1996-04-18 | 1998-07-14 | Elizabeth Arden Co. | Method for reducing human body cellulite by treatment with pulsed electromagnetic energy |
US5877627A (en) * | 1993-10-14 | 1999-03-02 | Dr. Fischer Aktiengesellschaft | Device for detecting secondary magnetic fields induced in an organism by pulsed magnetic fields |
US5908444A (en) * | 1997-06-19 | 1999-06-01 | Healing Machines, Inc. | Complex frequency pulsed electromagnetic generator and method of use |
US6083149A (en) * | 1997-10-22 | 2000-07-04 | Emf Therapeutics, Inc. | Magnetic field device and method for inhibiting angiogenesis and retarding growth rates of tumors in mammals |
US6086525A (en) * | 1994-11-28 | 2000-07-11 | Neotonus, Inc. | Magnetic nerve stimulator for exciting peripheral nerves |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6200259B1 (en) * | 1999-06-03 | 2001-03-13 | Keith L. March | Method of treating cardiovascular disease by angiogenesis |
US6213934B1 (en) * | 1995-06-01 | 2001-04-10 | Hyper3D Corp. | Electromagnetic bone-assessment and treatment: apparatus and method |
US6231528B1 (en) * | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
US6234953B1 (en) * | 1996-06-06 | 2001-05-22 | Lawson Research Institute | Electrotherapy device using low frequency magnetic pulses |
US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US20010007937A1 (en) * | 1998-12-17 | 2001-07-12 | Mackin Robert A. | Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue |
US6261221B1 (en) * | 1996-11-01 | 2001-07-17 | Amei Technologies Inc. | Flexible coil pulsed electromagnetic field (PEMF) stimulation therapy system |
US6261831B1 (en) * | 1999-03-26 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Air Force | Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat |
US20020035358A1 (en) * | 2000-05-09 | 2002-03-21 | Ming Wang | Pulsed electromagnetic field therapy for treatment of corneal disorders and injuries |
US6418345B1 (en) * | 1998-08-03 | 2002-07-09 | Amei Technologies Inc. | PEMF stimulator for treating osteoporosis and stimulating tissue growth |
US6421562B1 (en) * | 2000-07-17 | 2002-07-16 | Jesse Ross | Alternative treatment of a nonsurgically treatable intracranial occlusion |
US6424863B1 (en) * | 1999-03-26 | 2002-07-23 | Stephen T. Flock | Delivery of pharmaceutical compounds and collection of biomolecules using electromagnetic energy and uses thereof |
US20030023283A1 (en) * | 1998-11-30 | 2003-01-30 | Mcdaniel David H. | Method and apparatus for the stimulation of hair growth |
US20030028072A1 (en) * | 2000-08-31 | 2003-02-06 | Neuropace, Inc. | Low frequency magnetic neurostimulator for the treatment of neurological disorders |
US6556872B2 (en) * | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) * | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6561968B1 (en) * | 1999-08-31 | 2003-05-13 | Biofields Aps | Method and an apparatus for stimulating/ modulating biochemical processes using pulsed electromagnetic fields |
US20030093028A1 (en) * | 2001-11-09 | 2003-05-15 | Michael Spiegel | Appararus and method for magnetic induction of therapeutic electric fields |
US6569654B2 (en) * | 1998-09-18 | 2003-05-27 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of stem cells |
US20030099979A1 (en) * | 2001-08-07 | 2003-05-29 | Genox Research, Inc. | Method of testing for bronchial asthma |
US20030125769A1 (en) * | 2000-02-23 | 2003-07-03 | Brighton Carl T. | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
US6589159B2 (en) * | 2001-04-12 | 2003-07-08 | Sumathi Paturu | Magnetic therapy devices and methods |
US6675047B1 (en) * | 1999-06-28 | 2004-01-06 | Sergei Petrovich Konoplev | Electromagnetic-field therapy method and device |
US6678562B1 (en) * | 2000-01-12 | 2004-01-13 | Amei Technologies Inc. | Combined tissue/bone growth stimulator and external fixation device |
US6684108B2 (en) * | 1996-12-30 | 2004-01-27 | Indnjc, Inc. | Therapeutic and diagnostic apparatus and method |
US6701185B2 (en) * | 2002-02-19 | 2004-03-02 | Daniel Burnett | Method and apparatus for electromagnetic stimulation of nerve, muscle, and body tissues |
US6839589B2 (en) * | 2001-09-25 | 2005-01-04 | Jiri Joseph Petlan | Method and apparatus for treatment of living matter using pulsed radio frequency electromagnetic radiation |
US6844378B1 (en) * | 2002-01-04 | 2005-01-18 | Sandia Corporation | Method of using triaxial magnetic fields for making particle structures |
US20050049640A1 (en) * | 2003-05-12 | 2005-03-03 | Gurtner Geoffrey C. | Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2 |
US20050059153A1 (en) * | 2003-01-22 | 2005-03-17 | George Frank R. | Electromagnetic activation of gene expression and cell growth |
US6919205B2 (en) * | 2000-02-23 | 2005-07-19 | The Trustees Of The University Of Pennsylvania | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals |
US20060009825A1 (en) * | 2001-10-29 | 2006-01-12 | Chiriaev Viatcheslav M | Method and device for physiotherapy |
US7010353B2 (en) * | 2002-01-07 | 2006-03-07 | Ebi, L.P. | Non-invasive capacitively coupled electrical stimulation device for treatment of soft tissue wounds |
US7022506B2 (en) * | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US7160241B1 (en) * | 2000-10-06 | 2007-01-09 | Ewa Herbst | Treatment of living tissues using electromagnetic fields |
US20070026514A1 (en) * | 2005-03-07 | 2007-02-01 | Pilla Arthur A | Electromagnetic treatment apparatus for enhancing pharmacological, chemical, and topical agent effectiveness and method for using same |
US7175587B2 (en) * | 2002-12-31 | 2007-02-13 | Em-Probe, Inc. | Method and apparatus for pulsed electromagnetic therapy |
US7177696B1 (en) * | 1999-06-09 | 2007-02-13 | H & P Medical Research, Inc. | Multiple selectable field/current-voltage pads having individually powered and controlled cells |
US7177695B2 (en) * | 2001-12-17 | 2007-02-13 | Cefamoptec Industries, Inc. | Early stage wound healing using electromagnetic radiation |
US7215995B2 (en) * | 2003-11-14 | 2007-05-08 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
US7333858B2 (en) * | 2004-03-31 | 2008-02-19 | Cochlear Limited | Pulse burst electrical stimulation of nerve or tissue fibers |
US20080058793A1 (en) * | 2006-06-12 | 2008-03-06 | Pilla Arthur A | Electromagnetic apparatus for prophylaxis and repair of ophthalmic tissue and method for using same |
US20080132971A1 (en) * | 2006-09-20 | 2008-06-05 | Pille Arthur A | Electromagnetic apparatus for respiratory disease and method for using same |
US20080140155A1 (en) * | 2005-03-07 | 2008-06-12 | Pilla Arthur A | Excessive fibrous capsule formation and capsular contracture apparatus and method for using same |
US20090030476A1 (en) * | 2002-02-04 | 2009-01-29 | Hargrove Jeffrey B | Methods and Apparatus for Electrical Stimulation of Tissues Using Signals that Minimize the Effects of Tissue Impedance |
US20090099623A1 (en) * | 2004-09-13 | 2009-04-16 | Neuronix Ltd. | Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions |
US7520849B1 (en) * | 2004-09-20 | 2009-04-21 | Ebi, Lp | Pulsed electromagnetic field method of treating soft tissue wounds |
US7740574B2 (en) * | 2004-04-26 | 2010-06-22 | Ivivi Technologies, Inc. | Electromagnetic treatment induction apparatus and method for using same |
US7744524B2 (en) * | 2003-12-05 | 2010-06-29 | Ivivi Health Sciences, Llc | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US7896797B2 (en) * | 2007-04-12 | 2011-03-01 | Ivivi Health Sciences, Llc | Electromagnetic field treatment apparatus and method for using same |
US20110112352A1 (en) * | 2003-12-05 | 2011-05-12 | Pilla Arthur A | Apparatus and method for electromagnetic treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550714A (en) * | 1983-03-09 | 1985-11-05 | Electro-Biology, Inc. | Electromagnetic coil insert for an orthopedic cast or the like |
US4765310A (en) * | 1985-11-01 | 1988-08-23 | Dynatens Research Corporation | Electrical and magnetic pain treatment device |
US7465566B2 (en) * | 2000-02-23 | 2008-12-16 | The Trustees Of The University Of Pennsylvania | Regulation of genes via application of specific and selective electrical and electromagnetic signals |
US6733435B2 (en) * | 2002-03-08 | 2004-05-11 | Canedo Luis | Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain, edema, inflammation and infection |
MXPA06012077A (en) * | 2004-04-19 | 2007-04-23 | Ivivi Technologies Inc | Electromagnetic treatment apparatus and method. |
-
2004
- 2004-12-03 US US11/003,108 patent/US7744524B2/en active Active
- 2004-12-04 JP JP2006542819A patent/JP2007524476A/en active Pending
- 2004-12-04 CA CA002548270A patent/CA2548270A1/en not_active Abandoned
- 2004-12-04 EP EP04813038A patent/EP1694409A2/en not_active Ceased
- 2004-12-04 AU AU2004296198A patent/AU2004296198A1/en not_active Abandoned
- 2004-12-04 BR BRPI0417129-2A patent/BRPI0417129A/en not_active IP Right Cessation
- 2004-12-04 WO PCT/US2004/040646 patent/WO2005056111A2/en active Application Filing
- 2004-12-04 NZ NZ548283A patent/NZ548283A/en unknown
-
2006
- 2006-06-05 IL IL176126A patent/IL176126A0/en unknown
-
2010
- 2010-04-30 US US12/772,002 patent/US20100222631A1/en not_active Abandoned
- 2010-04-30 US US12/771,954 patent/US20100210893A1/en not_active Abandoned
-
2013
- 2013-10-21 US US14/058,764 patent/US20140046115A1/en not_active Abandoned
- 2013-10-21 US US14/058,973 patent/US20140046117A1/en not_active Abandoned
-
2016
- 2016-11-11 US US15/349,921 patent/US20170266458A1/en not_active Abandoned
Patent Citations (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1233841A (en) * | 1914-05-12 | 1917-07-17 | Marconi Wireless Telegraph Co America | Means for receiving electrical oscillations. |
US2276996A (en) * | 1940-11-30 | 1942-03-17 | A J Ginsberg | Non-radio-interfering therapeutic apparatus |
US3181535A (en) * | 1957-10-04 | 1965-05-04 | Diapulse Mfg Corp Of America | Athermapeutic apparatus |
US3043310A (en) * | 1959-04-24 | 1962-07-10 | Diapulse Mfg Corp Of America | Treatment head for athermapeutic apparatus |
US3329149A (en) * | 1964-10-28 | 1967-07-04 | Dynapower Systems Corp Of Cali | Supporting arm for electrotherapeutic treatment head |
US3329148A (en) * | 1965-09-21 | 1967-07-04 | Dynapower Systems Corp Of Cali | Control of electrotherapeutic apparatus |
US3890953A (en) * | 1971-04-06 | 1975-06-24 | Werner Kraus | Electrical apparatus generating a low frequency, alternating magnetic field for promoting the growth of bone and other body tissues |
US3800802A (en) * | 1972-01-07 | 1974-04-02 | Int Medical Electronics Ltd | Short-wave therapy apparatus |
US4028518A (en) * | 1974-06-18 | 1977-06-07 | L'oreal | Device for superficially heating an adjacent body |
US3952751A (en) * | 1975-01-08 | 1976-04-27 | W. Denis Kendall | High-performance electrotherapeutic apparatus |
US4266532A (en) * | 1976-11-17 | 1981-05-12 | Electro-Biology, Inc. | Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment |
US4315503A (en) * | 1976-11-17 | 1982-02-16 | Electro-Biology, Inc. | Modification of the growth, repair and maintenance behavior of living tissues and cells by a specific and selective change in electrical environment |
US4197851A (en) * | 1977-04-14 | 1980-04-15 | Fellus Victor M | Apparatus for emitting high-frequency electromagnetic waves |
US4338945A (en) * | 1978-03-03 | 1982-07-13 | Clinical Engineering Laboratory Limited | Method and randomized electrical stimulation system for pain relief |
US4340063A (en) * | 1980-01-02 | 1982-07-20 | Empi, Inc. | Stimulation device |
US4374482A (en) * | 1980-12-23 | 1983-02-22 | Norlin Industries, Inc. | Vocal effect for musical instrument |
US4428366A (en) * | 1981-05-06 | 1984-01-31 | Alfred B. Kurtz | Electromagnetic apparatus and method for the reduction of serum glucose levels |
US4454882A (en) * | 1981-07-29 | 1984-06-19 | Olympus Optical Co., Ltd. | Laser apparatus utilizing marking laser for triggering operative laser |
US4556051A (en) * | 1982-11-05 | 1985-12-03 | Empi, Inc. | Method and apparatus for healing tissue |
US4654574A (en) * | 1983-06-29 | 1987-03-31 | Sheldon Thaler | Apparatus for reactively applying electrical energy pulses to a living body |
US4829984A (en) * | 1983-12-15 | 1989-05-16 | Gordon Robert T | Method for the improvement of transplantation techniques and for the preservation of tissue |
US4548208A (en) * | 1984-06-27 | 1985-10-22 | Medtronic, Inc. | Automatic adjusting induction coil treatment device |
US4674482A (en) * | 1984-09-12 | 1987-06-23 | Irt, Inc. | Pulse electro-magnetic field therapy device with auto bias circuit |
US4672951A (en) * | 1985-12-30 | 1987-06-16 | Bio-Electric, Inc. | Method and apparatus for treatment of biological tissue |
US4998532A (en) * | 1986-05-23 | 1991-03-12 | Lti Biomedical, Inc. | Portable electro-therapy system |
US5000178A (en) * | 1986-05-23 | 1991-03-19 | Lti Biomedical, Inc. | Shielded electromagnetic transducer |
US5014699A (en) * | 1986-05-23 | 1991-05-14 | Trustees Of The University Of Pennsylvania | Electromagnetic method and apparatus for healing living tissue |
US4926881A (en) * | 1987-06-15 | 1990-05-22 | Matsushita Electric Works, Ltd. | Portable battery powered electromagnetic therapy applicator |
US4850372A (en) * | 1987-08-25 | 1989-07-25 | The Johns Hopkins University | Electromagnetic non-invasive measurement and monitoring system for osteoporosis |
US5529569A (en) * | 1987-09-08 | 1996-06-25 | Woo; Gilson | Treatment of ailments, afflections and diseases |
US5123898A (en) * | 1988-03-23 | 1992-06-23 | Life Resonances, Inc. | Method and apparatus for controlling tissue growth with an applied fluctuating magnetic field |
US5518496A (en) * | 1988-03-23 | 1996-05-21 | Life Resonances, Inc. | Deformable magnetic field aiding coils for use in controlling tissue growth |
US5224922A (en) * | 1988-05-19 | 1993-07-06 | Kurtz Warren H | Quasistatic biological cell and tissue modifier |
US4993413A (en) * | 1988-09-22 | 1991-02-19 | The Research Foundation Of State University Of New York | Method and apparatus for inducing a current and voltage in living tissue |
US5147284A (en) * | 1989-08-17 | 1992-09-15 | Fedorov Svjatoslav N | Device and method for restoration of visual functions |
US5181902A (en) * | 1990-09-21 | 1993-01-26 | American Medical Electronics, Inc. | Double-transducer system for PEMF Therapy |
US5480373A (en) * | 1991-07-09 | 1996-01-02 | Dr. Fischer Aktiengesellschaft | Device for transporting ions, in particular, protons |
US5338286A (en) * | 1992-12-08 | 1994-08-16 | Electro-Biology, Inc. | Electromagnetic bioresponse by selective spectral suppression in pulsed field stimulation |
US5386837A (en) * | 1993-02-01 | 1995-02-07 | Mmtc, Inc. | Method for enhancing delivery of chemotherapy employing high-frequency force fields |
US5877627A (en) * | 1993-10-14 | 1999-03-02 | Dr. Fischer Aktiengesellschaft | Device for detecting secondary magnetic fields induced in an organism by pulsed magnetic fields |
US5595564A (en) * | 1993-11-26 | 1997-01-21 | Biofarm S.R.L. | Device for retarding hair loss and for stimulating its regrowth |
US5407421A (en) * | 1994-05-18 | 1995-04-18 | Goldsmith; Seth | Compressive brace |
US5723001A (en) * | 1994-06-09 | 1998-03-03 | Electropharmacology, Inc. | Apparatus and method for therapeutically treating human body tissue with electromagnetic radiation |
US6086525A (en) * | 1994-11-28 | 2000-07-11 | Neotonus, Inc. | Magnetic nerve stimulator for exciting peripheral nerves |
US6213934B1 (en) * | 1995-06-01 | 2001-04-10 | Hyper3D Corp. | Electromagnetic bone-assessment and treatment: apparatus and method |
US5718246A (en) * | 1996-01-03 | 1998-02-17 | Preferential, Inc. | Preferential induction of electrically mediated cell death from applied pulses |
US5778894A (en) * | 1996-04-18 | 1998-07-14 | Elizabeth Arden Co. | Method for reducing human body cellulite by treatment with pulsed electromagnetic energy |
US6234953B1 (en) * | 1996-06-06 | 2001-05-22 | Lawson Research Institute | Electrotherapy device using low frequency magnetic pulses |
US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US5743844A (en) * | 1996-11-01 | 1998-04-28 | Amei Technologies, Inc. | High efficiency pulsed electromagnetic field (PEMF) stimulation therapy method and system |
US6261221B1 (en) * | 1996-11-01 | 2001-07-17 | Amei Technologies Inc. | Flexible coil pulsed electromagnetic field (PEMF) stimulation therapy system |
US5718721A (en) * | 1996-12-23 | 1998-02-17 | Ross; Jesse | Method of relieving migraine headache pain |
US6684108B2 (en) * | 1996-12-30 | 2004-01-27 | Indnjc, Inc. | Therapeutic and diagnostic apparatus and method |
US5908444A (en) * | 1997-06-19 | 1999-06-01 | Healing Machines, Inc. | Complex frequency pulsed electromagnetic generator and method of use |
US6083149A (en) * | 1997-10-22 | 2000-07-04 | Emf Therapeutics, Inc. | Magnetic field device and method for inhibiting angiogenesis and retarding growth rates of tumors in mammals |
US6418345B1 (en) * | 1998-08-03 | 2002-07-09 | Amei Technologies Inc. | PEMF stimulator for treating osteoporosis and stimulating tissue growth |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6569654B2 (en) * | 1998-09-18 | 2003-05-27 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of stem cells |
US20030023283A1 (en) * | 1998-11-30 | 2003-01-30 | Mcdaniel David H. | Method and apparatus for the stimulation of hair growth |
US20010007937A1 (en) * | 1998-12-17 | 2001-07-12 | Mackin Robert A. | Apparatus and method for contemporaneous treatment and fluoroscopic mapping of body tissue |
US6231528B1 (en) * | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
US6424863B1 (en) * | 1999-03-26 | 2002-07-23 | Stephen T. Flock | Delivery of pharmaceutical compounds and collection of biomolecules using electromagnetic energy and uses thereof |
US6261831B1 (en) * | 1999-03-26 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Air Force | Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat |
US6200259B1 (en) * | 1999-06-03 | 2001-03-13 | Keith L. March | Method of treating cardiovascular disease by angiogenesis |
US7177696B1 (en) * | 1999-06-09 | 2007-02-13 | H & P Medical Research, Inc. | Multiple selectable field/current-voltage pads having individually powered and controlled cells |
US6675047B1 (en) * | 1999-06-28 | 2004-01-06 | Sergei Petrovich Konoplev | Electromagnetic-field therapy method and device |
US6556872B2 (en) * | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) * | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6561968B1 (en) * | 1999-08-31 | 2003-05-13 | Biofields Aps | Method and an apparatus for stimulating/ modulating biochemical processes using pulsed electromagnetic fields |
US6678562B1 (en) * | 2000-01-12 | 2004-01-13 | Amei Technologies Inc. | Combined tissue/bone growth stimulator and external fixation device |
US20030125769A1 (en) * | 2000-02-23 | 2003-07-03 | Brighton Carl T. | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals |
US6919205B2 (en) * | 2000-02-23 | 2005-07-19 | The Trustees Of The University Of Pennsylvania | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals |
US7022506B2 (en) * | 2000-02-23 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee |
US20020035358A1 (en) * | 2000-05-09 | 2002-03-21 | Ming Wang | Pulsed electromagnetic field therapy for treatment of corneal disorders and injuries |
US6421562B1 (en) * | 2000-07-17 | 2002-07-16 | Jesse Ross | Alternative treatment of a nonsurgically treatable intracranial occlusion |
US20030028072A1 (en) * | 2000-08-31 | 2003-02-06 | Neuropace, Inc. | Low frequency magnetic neurostimulator for the treatment of neurological disorders |
US7160241B1 (en) * | 2000-10-06 | 2007-01-09 | Ewa Herbst | Treatment of living tissues using electromagnetic fields |
US6589159B2 (en) * | 2001-04-12 | 2003-07-08 | Sumathi Paturu | Magnetic therapy devices and methods |
US20030099979A1 (en) * | 2001-08-07 | 2003-05-29 | Genox Research, Inc. | Method of testing for bronchial asthma |
US6839589B2 (en) * | 2001-09-25 | 2005-01-04 | Jiri Joseph Petlan | Method and apparatus for treatment of living matter using pulsed radio frequency electromagnetic radiation |
US20060009825A1 (en) * | 2001-10-29 | 2006-01-12 | Chiriaev Viatcheslav M | Method and device for physiotherapy |
US20030093028A1 (en) * | 2001-11-09 | 2003-05-15 | Michael Spiegel | Appararus and method for magnetic induction of therapeutic electric fields |
US7177695B2 (en) * | 2001-12-17 | 2007-02-13 | Cefamoptec Industries, Inc. | Early stage wound healing using electromagnetic radiation |
US6844378B1 (en) * | 2002-01-04 | 2005-01-18 | Sandia Corporation | Method of using triaxial magnetic fields for making particle structures |
US7010353B2 (en) * | 2002-01-07 | 2006-03-07 | Ebi, L.P. | Non-invasive capacitively coupled electrical stimulation device for treatment of soft tissue wounds |
US20090030476A1 (en) * | 2002-02-04 | 2009-01-29 | Hargrove Jeffrey B | Methods and Apparatus for Electrical Stimulation of Tissues Using Signals that Minimize the Effects of Tissue Impedance |
US6701185B2 (en) * | 2002-02-19 | 2004-03-02 | Daniel Burnett | Method and apparatus for electromagnetic stimulation of nerve, muscle, and body tissues |
US7175587B2 (en) * | 2002-12-31 | 2007-02-13 | Em-Probe, Inc. | Method and apparatus for pulsed electromagnetic therapy |
US20050059153A1 (en) * | 2003-01-22 | 2005-03-17 | George Frank R. | Electromagnetic activation of gene expression and cell growth |
US20050049640A1 (en) * | 2003-05-12 | 2005-03-03 | Gurtner Geoffrey C. | Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2 |
US7215995B2 (en) * | 2003-11-14 | 2007-05-08 | The Trustees Of The University Of Pennsylvania | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
US7744524B2 (en) * | 2003-12-05 | 2010-06-29 | Ivivi Health Sciences, Llc | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US20140046115A1 (en) * | 2003-12-05 | 2014-02-13 | Arthur A. Pilla | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US20140046117A1 (en) * | 2003-12-05 | 2014-02-13 | Arthur A. Pilla | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules |
US20110112352A1 (en) * | 2003-12-05 | 2011-05-12 | Pilla Arthur A | Apparatus and method for electromagnetic treatment |
US7333858B2 (en) * | 2004-03-31 | 2008-02-19 | Cochlear Limited | Pulse burst electrical stimulation of nerve or tissue fibers |
US7740574B2 (en) * | 2004-04-26 | 2010-06-22 | Ivivi Technologies, Inc. | Electromagnetic treatment induction apparatus and method for using same |
US20090099623A1 (en) * | 2004-09-13 | 2009-04-16 | Neuronix Ltd. | Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions |
US7520849B1 (en) * | 2004-09-20 | 2009-04-21 | Ebi, Lp | Pulsed electromagnetic field method of treating soft tissue wounds |
US20080140155A1 (en) * | 2005-03-07 | 2008-06-12 | Pilla Arthur A | Excessive fibrous capsule formation and capsular contracture apparatus and method for using same |
US20070026514A1 (en) * | 2005-03-07 | 2007-02-01 | Pilla Arthur A | Electromagnetic treatment apparatus for enhancing pharmacological, chemical, and topical agent effectiveness and method for using same |
US20080058793A1 (en) * | 2006-06-12 | 2008-03-06 | Pilla Arthur A | Electromagnetic apparatus for prophylaxis and repair of ophthalmic tissue and method for using same |
US20080132971A1 (en) * | 2006-09-20 | 2008-06-05 | Pille Arthur A | Electromagnetic apparatus for respiratory disease and method for using same |
US7896797B2 (en) * | 2007-04-12 | 2011-03-01 | Ivivi Health Sciences, Llc | Electromagnetic field treatment apparatus and method for using same |
US20110152598A1 (en) * | 2007-04-12 | 2011-06-23 | Pilla Arthur A | Electromagnetic field treatment apparatus and method for using same |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9440089B2 (en) | 2003-12-05 | 2016-09-13 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
US10226640B2 (en) | 2003-12-05 | 2019-03-12 | Endonovo Therapeutics, Inc. | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US9433797B2 (en) | 2003-12-05 | 2016-09-06 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
US9656096B2 (en) | 2003-12-05 | 2017-05-23 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US10207122B2 (en) | 2003-12-05 | 2019-02-19 | Endonovo Therapeutics, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
US9415233B2 (en) | 2003-12-05 | 2016-08-16 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological pain |
US8961385B2 (en) | 2003-12-05 | 2015-02-24 | Ivivi Health Sciences, Llc | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
US8415123B2 (en) | 2004-04-19 | 2013-04-09 | Ivivi Health Sciences, Llc | Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells |
US9849299B2 (en) | 2007-05-03 | 2017-12-26 | Orthocor Medical, Inc. | Disposable, single-use thermal exchange component |
US9968797B2 (en) | 2007-05-03 | 2018-05-15 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US9387339B2 (en) | 2007-05-03 | 2016-07-12 | Orthocor Medical, Inc. | Disposable, single-use thermal exchange component |
US20110004261A1 (en) * | 2007-05-03 | 2011-01-06 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US8768454B2 (en) | 2007-05-03 | 2014-07-01 | Orthocor Medical, Inc. | Electromagnetic thermal therapy |
US20110065977A1 (en) * | 2007-05-03 | 2011-03-17 | Orthocor Medical, Inc. | Disposable, single-use thermal exchange component |
US20090132010A1 (en) * | 2007-11-19 | 2009-05-21 | Kronberg James W | System and method for generating complex bioelectric stimulation signals while conserving power |
US9427598B2 (en) | 2010-10-01 | 2016-08-30 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans |
US8343027B1 (en) | 2012-01-30 | 2013-01-01 | Ivivi Health Sciences, Llc | Methods and devices for providing electromagnetic treatment in the presence of a metal-containing implant |
US9227080B2 (en) | 2012-05-31 | 2016-01-05 | Richard A. Rogachefsky | Applicable device for healing injuries with magnetic fields |
WO2013181144A1 (en) * | 2012-05-31 | 2013-12-05 | Rogachefsky Richard A | Applicable device for healing injuries with magnetic fields |
US9320913B2 (en) | 2014-04-16 | 2016-04-26 | Rio Grande Neurosciences, Inc. | Two-part pulsed electromagnetic field applicator for application of therapeutic energy |
US10350428B2 (en) | 2014-11-04 | 2019-07-16 | Endonovo Therapetics, Inc. | Method and apparatus for electromagnetic treatment of living systems |
US10335282B2 (en) | 2016-02-09 | 2019-07-02 | Richard A. Rogachefsky | Magnetic joint replacement |
US11826579B2 (en) | 2016-11-10 | 2023-11-28 | Mannavibes Inc. | System and method for applying a low frequency magnetic field to biological tissues |
US10806942B2 (en) | 2016-11-10 | 2020-10-20 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
US11344741B2 (en) | 2016-11-10 | 2022-05-31 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
US10870013B2 (en) | 2017-05-08 | 2020-12-22 | Aah Holdings Llc | Multi-coil electromagnetic apparatus |
US11338150B2 (en) | 2017-05-08 | 2022-05-24 | Aah Holdings, Llc | Multi-coil electromagnetic apparatus |
US11071876B2 (en) | 2018-12-03 | 2021-07-27 | Aah Holdings Llc | Apparatus and method for treatment of mental and behavioral conditions and disorders with electromagnetic fields |
Also Published As
Publication number | Publication date |
---|---|
US20140046115A1 (en) | 2014-02-13 |
US7744524B2 (en) | 2010-06-29 |
WO2005056111A2 (en) | 2005-06-23 |
CA2548270A1 (en) | 2005-06-23 |
AU2004296198A1 (en) | 2005-06-23 |
US20100210893A1 (en) | 2010-08-19 |
NZ548283A (en) | 2008-06-30 |
US20050197522A1 (en) | 2005-09-08 |
EP1694409A2 (en) | 2006-08-30 |
US20170266458A1 (en) | 2017-09-21 |
IL176126A0 (en) | 2006-10-05 |
WO2005056111A3 (en) | 2005-11-10 |
BRPI0417129A (en) | 2007-03-06 |
JP2007524476A (en) | 2007-08-30 |
US20140046117A1 (en) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7744524B2 (en) | Apparatus and method for electromagnetic treatment of plant, animal, and human tissue, organs, cells, and molecules | |
US10226640B2 (en) | Devices and method for treatment of degenerative joint diseases with electromagnetic fields | |
US8415123B2 (en) | Electromagnetic treatment apparatus and method for angiogenesis modulation of living tissues and cells | |
US7758490B2 (en) | Integrated coil apparatus for therapeutically treating human and animal cells, tissues and organs with electromagnetic fields and method for using same | |
EP1868591B1 (en) | Pharmacological, chemical, and topical agent enhancement apparatus | |
US20060212077A1 (en) | Electromagnetic treatment apparatus for augmenting wound repair and method for using same | |
US20070173904A1 (en) | Self-contained electromagnetic apparatus for treatment of molecules, cells, tissues, and organs within a cerebrofacial area and method for using same | |
US20130218235A9 (en) | Excessive fibrous capsule formation and capsular contracture apparatus and method for using same | |
ZA200605544B (en) | Electromagnetic treatment apparatus and method | |
MXPA06006368A (en) | Electromagnetic treatment apparatus and method | |
KR20070015908A (en) | Electromagnetic treatment apparatus and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IVIVI HEALTH SCIENCES, LLC, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:IVIVI TECHNOLOGIES, LLC;REEL/FRAME:027259/0426 Effective date: 20100212 Owner name: IVIVI TECHNOLOGIES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PILLA, ARTHUR A.;REEL/FRAME:027257/0634 Effective date: 20100514 Owner name: IVIVI TECHNOLOGIES, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVIVI TECHNOLOGIES, INC.;REEL/FRAME:027263/0615 Effective date: 20100212 |
|
AS | Assignment |
Owner name: IVIVI TECHNOLOGIES, INC., CALIFORNIA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE COVER SHEET PREVIOUSLY RECORDED ON REEL 027257 FRAME 0634. ASSIGNOR(S) HEREBY CONFIRMS THE EXECUTION DATE IS 12/03/2004 AND NOT 05/14/2010;ASSIGNOR:PILLA, ARTHUR A.;REEL/FRAME:036687/0022 Effective date: 20041203 |
|
AS | Assignment |
Owner name: RIO GRANDE NEUROSCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVIVI HEALTH SCIENCES, LLC;REEL/FRAME:037394/0244 Effective date: 20151223 |
|
AS | Assignment |
Owner name: RIO GRANDE NEUROSCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IVIVI HEALTH SCIENCES, LLC;REEL/FRAME:037445/0365 Effective date: 20151223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |